document incorporate reference incorporate scheringplough corporation proxy statement annual meeting shareholder iiitable content p age item business item risk factor item b unresolved staff comment item property item legal proceeding item submission matter vote security holder executive officer registrant ii item market registrant common equity relate stockholder matter item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure management report internal control financial reporting iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction item principal accountant fee service iv item exhibit financial statement schedule signature exev employment agreement exevi employment agreement exeviii employment agreement exeix form change employment agreement exl supplemental executive retirement plan ex computation ratio earning fix charge ex subsidiary ex consent independent register public accounting firm ex independent auditor consent ex power attorney ex certification ex certification ex certification ex certification table content item business overview business scheringplough refer scheringplough corporation subsidiary indicate context schering corporation predecessor company incorporate new york new jersey trademark indicate capital letter k property license promote distribute scheringplough corporation subsidiary relate company scheringplough global sciencebase health care company lead prescription consumer animal health product internal research collaboration business partner scheringplough discover develop manufacture market advanced drug therapy meet important medical need scheringplough vision earn trust physician patient customer serve world shareholder scheringplough scheringplough worldwide headquarters kenilworth new jersey website wwwscheringploughcom april board director name fred hassan new chairman board chief executive officer scheringplough leadership strategic plan initiate goal stabilize repair turn scheringplough produce longterm value shareholder plan eightyear action agenda implement new leadership team recruit mr hassan scheringplough announce enter fourth action agenda phase slightly ahead schedule segment information new management team reorganize business manage geographic line primary segment restofworld business organize product currently scheringplough reportable segment prescription pharmaceutical consumer health care animal health segment sale profit datum follow consistent scheringplough current management reporting structure prescription pharmaceutical prescription pharmaceutical segment discover develop manufacture market human pharmaceutical product prescription pharmaceutical segment area focus primary care specialty care cholesterol franchise principal product segment include primary care allergyrespiratory nasonex oncedaily nasalinhale steroid nasal allergy symptom include congestion treatment nasal polyp patient year age old clarinex nonsedate antihistamine treatment allergic rhinitis foradil aerolizer longacting betaagonist market scheringplough united states maintenance treatment asthma chronic obstructive pulmonary disease acute prevention exerciseinduce bronchospasm asmanex twisthaler oral drypowder corticosteroid inhaler firstline maintenance treatment asthma proventil albuterol inhaler relief bronchospasm patient year old antibiotic avelox broadspectrum fluoroquinolone antibiotic certain respiratory skin infection cipro broadspectrum fluoroquinolone antibiotic certain respiratory skin urinary tract infection dermatological elocon mediumpotency topical steroid cream lotion ointment disorder levitra phosphodiesterase type inhibitor pde comarketed scheringplough united states treatment male erectile dysfunction table content specialty care antiinflammatorie remicade antitnf antibody market scheringplough outside united states japan certain asian market treatment rheumatoid arthritis crohns disease ankylose spondylitis ulcerative colitis psoriatic arthritis psoriasis firstline therapy treatment early rheumatoid arthritis antiviral pegintron powder injection pegylate interferon product chronic hepatitis c approve dosing accord patient body weight intron injection chronic hepatitis b c antiviral indication rebetol capsule use pegintron intron chronic hepatitis c oncology temodar capsule certain type brain tumor include newly diagnose glioblastoma multiforme caelyx longcirculating pegylate liposomal formulation cancer drug doxorubicin market scheringplough outside united states treatment certain ovarian cancer kaposis sarcoma metastatic breast cancer intron injection market numerous anticancer indication worldwide include adjuvant therapy malignant melanoma antifungal noxafil oral suspension prophylaxis prevention treatment eu invasive fungal infection highrisk patient treatment oropharyngeal candidiasis eu acute coronary care integrilin injection platelet receptor gp iibiiia inhibitor treatment patient acute coronary syndrome undergo percutaneous coronary intervention united states prevention early myocardial infarction patient acute coronary syndrome country disorder subutex sublingual tablet formulation buprenorphine suboxone sublingual tablet combination buprenorphine naloxone market schering plough certain country outside united states treatment opiate addiction cholesterol franchise zetia novel cholesterolabsorption inhibitor discover scheringplough scientist use monotherapy combination statin fenofibrate low cholesterol vytorin cholesterollowere tablet combine dual action zetia merck co inc statin zocor consumer health care consumer health care segment develop manufacture market otc foot care sun care product principal product segment include overthecounter otc product claritin nonsedate antihistamines drixoral cold allergy allergy sinus flu nasal decongestant tablet afrin nasal decongestant spray correctol laxative tablet foot care dr scholl foot care product lotrimin topical antifungal product tinactin topical antifungal product foot sneaker odorwetness product sun care coppertone sun care lotion spray dry oil lipprotection product sunless tanning product solarcaine sunburn relief product animal health animal health segment discover develop manufacture market animal health product principal product segment include livestock product nuflor bovine swine antibiotic banamine bovine swine antiinflammatory mpac swine pneumonia vaccine table content poultry product paracox coccivac coccidiosis vaccine poultry companion animal product otomax steroid otitis dog exspot topical insecticide dog homeagain pet recovery service zubrin anti inflammatoryanalgesic dog aquaculture product slice parasiticide sea lice salmon aquaflor antibiotic farmraised fish net sale segment ea r end decemb er dollar million prescription pharmaceutical consumer health care animal health consolidate net sale profit segment e r end decem r dollar million prescription pharmaceutical consumer health care animal health corporate include net interest income million million respectively million net interest expense consolidate profitloss tax cumulative effect change accounting principle scheringplough net sale include sale vytorin zetia manage partnership merck scheringplough account joint venture equity method accounting note equity income cholesterol joint venture item financial statement supplementary datum additional information equity income cholesterol joint venture include prescription pharmaceutical segment profit corporate include interest income expense foreign exchange gain loss headquarters expense special charge miscellaneous item accounting policy segment report describe note summary significant accounting policy item financial statement supplementary datum corporate include special charge million primarily relate change streamline scheringplough manufacturing operation puerto rico announce june relate prescription pharmaceutical segment include cost sale charge approximately million manufacturing streamlining action primarily relate prescription pharmaceutical segment corporate include special charge million include million employee termination cost million asset impairment charge increase litigation reserve million result total reserve approximately million represent scheringplough current estimate resolve massachusetts investigation investigation state litigation disclose awp litigation investigation note legal environmental regulatory matter item financial statement supplementary datum estimate charge relate reportable table content segment follow prescription pharmaceutical million consumer health care million animal health million corporate million corporate include special charge million include million employee termination cost million asset impairment charge estimate charge relate reportable segment follow prescription pharmaceutical million consumer health care million animal health million corporate million note special charge manufacture streamline item financial statement supplementary datum additional information strategic alliance scheringplough market product develop internal research product license business partner strategic alliance addition merckscheringplough joint venture strategic alliance centocor describe detail scheringplough engage number alliance include scheringplough exclusive right puerto rico strategic agreement bayer market sell distribute bayer avelox moxifloxacin hci cipro ciprofloxacin hci antibiotic undertake bayer commercialization activity erectile dysfunction medicine levitra vardenafil hci bayers co promotion agreement glaxosmithkline plc licensing agreement millenium pharmaceuticals inc scheringplough market integrilin eptifibatide injection gp iibiiia inhibitor certain country outside license agreement alza corporation division johnson johnson scheringplough markets caelyx outside united states japan israel treatment certain cancer caelyx market doxil ortho biotech product lp scheringplough exclusive marketing right suboxone subutex europe canada certain country suboxone subutex develop reckitt benckiser healthcare ltd treatment opioid dependence framework medical social psychological treatment product market reckitt benckiser pharmaceuticals inc scheringplough enter strategic alliance development commercialization new drug therapy include follow scheringplough global collaboration novartis ag develop commercialize new combination therapy new molecular entity nme treat asthma chronic obstructive pulmonary disease copd scheringploughs oncedaily inhale corticosteroid mometasone active ingredient asmanex mometasone furoate novartis oncedaily betaagonist indacaterol qab combine single inhalation device combination product oncedaily dose potential offer patient benefit include enhance disease control convenience scheringplough enter north american development marketing agreement alkabello tabletbase sublingual immunotherapy slit compound treatment certain allergy compound grasspollen allergy currently phase iii clinical development scheringplough enter definitive licensing agreement valeant pharmaceutical international metabasis therapeutics inc exclusive worldwide development commercial right pradefovir investigational oral antiviral compound currently phase ii clinical development treatment chronic hepatitis b scheringplough enter exclusive worldwide agreement anacor pharmaceutical develop market investigational compound topical treatment onychomycosis nail fungus compound currently phase ii clinical development table content scheringplough announce enter exclusive north american licensing agreement santarus inc development commercialization lowdose form zegerid overthecounter use heartburnrelated indication zegerid immediaterelease proton pump inhibitor currently sell prescription product information merckscheringplough joint venture scheringplough merck co inc merck enter separate set agreement jointly develop market certain product include cholesterollowere drug allergyasthma drug december cholesterol agreement expand include country world japan general company agree collaborative activity agreement operate virtual joint venture maximum degree possible rely respective infrastructure company cholesterol agreement provide jointly own facility product result collaboration manufacture facility own schere plough merck cholesterol agreement provide scheringplough merck jointly develop ezetimibe market zetia asia ezetrol europe oncedaily monotherapy ii coadministration statin drug iii oncedaily fixedcombination tablet ezetimibe simvastatin zocor merck cholesterolmodifye medicine combination medication ezetimibesimvastatin market vytorin inegy international country zetiaezetrol ezetimibe vytorininegy combination ezetimibesimvastatin approve use launch international market scheringplough utilize equity method accounting cholesterol joint venture note equity income cholesterol joint venture item financial statement supplemental datum additional information profit cost share accounting provide cholesterol agreement allergyasthma agreement provide joint development marketing partner oncedaily fixedcombination tablet contain claritin singulair singulair merck oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis january merckscheringplough respiratory joint venture report result phase iii clinical trial fixedcombination tablet contain claritin singulair phase iii study demonstrate sufficient add benefit treatment seasonal allergic rhinitis claritin singulair combination tablet approval country phase iii clinical development ongoing information centocor license remicade license manufactured centocor inc johnson johnson company scheringplough exclusive marketing right product outside japan certain asian market scheringplough exercise option contract centocor license right develop commercialize golimumab fully human monoclonal antibody territory remicade golimumab currently phase iii trial scheringplough centocor collaborate resolve difference party opinion expiration date scheringplough right golimumab august scheringplough receive determination arbitration right market golimumab extend year commercial sale territory centocor appeal rule global operation nonus operation generate majority scheringplough profit cash flow nonus activity carry primarily whollyowne subsidiary market potential adequate circumstance permit addition scheringplough represent market licensee distribution table content arrangement currently scheringplough business operation country approximately employee outside nonus operation subject certain risk inherent conduct business overseas risk include possible nationalization expropriation importation limitation pricing reimbursement restriction restrictive governmental action economic destabilization fluctuation foreign currency exchange rate impact scheringplough consolidated financial result additional information global operation item management discussion analysis segment information describe net sale geographic area dollar millions united states europe canada pacific area asia latin america total international consolidated net sale scheringplough subsidiary country outside net sale present geographic area scheringplough customer locate follow country account percent consolidated net sale past year consolidated net consolidated net consolidated net sale net sale sale net sale sale net sale dollar million total international net sale france japan canada italy net sale customer sale single customer account percent scheringploughs consolidate net sale past year follow consolidated net consolidated net consolidated net sale net sale sale net sale sale net sale dollar million mckesson corporation cardinal health table content supplemental sale information sale product comprise percent scheringplough international sale year end december follow mount p ercentage dollar million nasonex international remicade pegintron longlive assets geographic location dollar millions united states singapore ireland puerto rico total longlive asset show geographic location primarily property scheringplough disaggregate asset segment basis internal management report information present research development scheringplough research activity primarily aim discover develop new prescription product enhancement exist prescription product medical commercial significance companysponsore research development expenditure billion billion billion respectively percentage consolidated net sale research development expenditure represent approximately percent percent percent respectively scheringplough research activity concentrate therapeutic area respiratory disease inflammatory disease infectious disease oncology cardiovascular metabolic disease central nervous system disorder scheringplough substantial effort direct biotechnology immunology research activity include expenditure internal research effort research collaboration partner pharmaceutical compound vary stage development predict compound available commercial sale schering plough product pipeline list significant product development available scheringplough website wwwscheringploughcom nature development approval process fact human health involve science human health constantly evolve status compound development subject change schere plough assume duty update information scheringplough phase ii project grant fasttrack designation fda novel thrombin receptor antagonist acute coronary syndrome secondary prevention subsequent cardiovascular event vicriviroc hiv protease inhibitor compound hepatitis c new potential treatment patient parkinson disease product advance phase iii clinical trial significant expenditure require large number patient necessary phase iii trial table content patent trademark intellectual property right overview intellectual property protection critical scheringplough ability successfully commercialize product innovation scheringplough own apply license right large number patent country relate molecule product product use formulation manufacturing process assurance patent scheringplough seeking grant patent scheringplough grant find valid challenge patent relate particular molecule product use formulation process preclude manufacturer employ alternative process market alternative product formulation successfully compete scheringplough patent product outside standard intellectual property protection pharmaceutical vary widely country reasonably strong patent law country currently provide little effective protection invention intellectual property right traderelate aspect intellectual property agreement trip administer world trade organization wto country agree provide nondiscriminatory protection pharmaceutical invention assure adequate effective right available patent owner possible change agreement future diminish delay implementation develop country soon assess scheringplough impact commercially change product patent expire patent holder lose effective market exclusivity product result rapid sharp material decline sale patent product particularly case innovator company obtain additional commercial benefit manufacture trade secret laterexpire patent process use formulation trademark use exclusivity available pharmaceutical regulatory law scheringplough intellectual property portfolio patent protection certain scheringplough molecule product process use important scheringploughs business financial result scheringplough product addition patent compound scheringplough hold patent manufacturing process formulation use extend exclusivity expiration compound patent scheringplough subsidiary license right number patent patent application abroad patent patent application relate scheringplough significant product include limitation vytorin zetia remicade nasonex intron pegintron temodar clarinex material importance scheringplough worldwide scheringplough sell major product trademark material aggregate business financial result trademark protection vary world protection continue country long mark country long register registration normally fix renewable term patent challenge hatchwaxman act drug price competition patent term restoration act commonly know hatchwaxman complex set change patent new drug approval law hatchwaxman drug approve provide food drug administration fda complete safety efficacy study know complete new drug application nda hatchwaxman authorize fda approve generic version innovative medicine information file abbreviate new drug application anda anda generic manufacturer demonstrate bioequivalence generic version ndaapprove drug safety efficacy hatchwaxman provide limited patent term restoration partially patent term lose time ndaapprove drug regulatory review ndaapprove drug receive limited period datum exclusivity prevent approval anda application specific time period approval ndaapprove drug table content absent successful patent challenge fda approve anda innovators patent expire generic manufacturer file anda seek approval expiration applicable datum exclusivity allege patent list innovators nda invalid infringe allegation commonly know paragraph iv certification innovator file suit generic manufacturer protect patent ndaliste patent successfully challenge fil paragraph iv certification entitle day period market exclusivity generic manufacturer recent year generic manufacturer paragraph iv certification extensively challenge patent wide array innovative pharmaceutical anticipate trend continue number generic company file andas clarinex tablet reditab response scheringplough bring patent infringement action adverse outcome action result introduction generic desloratadine prior expiration patent subject litigation addition february schering plough receive notice generic company indicate file anda zetia challenge patent list zetia merck scheringplough consider appropriate response marketing activity competition scheringplough train professional sale representative introduce make know prescription drug physician pharmacist hospitals manage care organization buy group scheringplough sell prescription drug hospital certain manage care organization wholesale distributor retail pharmacist scheringplough introduce make know prescription product journal advertise direct mail advertising distribution sample physicians television radio internet print advertising medium scheringplough train professional sale representative promote animal health product veterinarian distributor animal producer scheringplough sell overthecounter foot care sun care product wholesale retail drug food chain mass merchandiser outlet scheringplough promote directly consumer television radio internet print advertising media pharmaceutical industry highly competitive include large company significantly large scheringplough substantial resource research product development advertising promotion field sell support numerous domestic international competitor industry principal competitive technique scheringplough product include research development new improve product vary dosage form strength switch prescription product nonprescription status scheringploughs product subject increasingly competitive pricing manage care group institution federal state government entity agency buy group seek price discount rebate governmental pressure dispense generic product significantly reduce sale certain product compete product therapeutic category long protect patent exclusivity available pharmaceutical regulatory law scheringplough operate primarily prescription pharmaceutical marketplace appropriate scheringplough seek regulatory approval switch prescription product overthecounter status mean extend product life cycle way otc marketplace mean maximize return investment discovery development government regulation scheringplough major business segment subject significant regulation multiple jurisdiction section describe general regulatory framework additional information cost regulatory compliance specific impact scheringplough business financial condition describe head regulatory competitive environment scheringplough operate item management discussion analysis additional information regulatory matter find table content item legal matter note consent decree note legal environmental regulatory matter item financial statement supplementary datum prescription drug segment regulation apply phase business include regulatory requirement conduct standard clinical trial example require use good clinical practice gcp apply research development stage regulatory requirement conduct standard postapproval clinical trial require regulatory approval begin market new drug market exist drug product new indication regulation prescribe manner drug manufacture package label advertise market distribute regulation impact pricing drug regulatory requirement assess report adverse impact effect drug clinical trial market drug call pharmacovigilance ability regulatory authority remove product market recall certain batch product national regulation phase prescription drug business price centralize food drug administration fda fda responsible protect public health assure safety efficacy security human veterinary drug biological product medical device generally free market pricing center medicare medicaid services cms medicare b include provision price drug elderly disabled indigent receive federal prescription benefit scheringplough commit comply voluntary good practice pharmaceutical research manufacturers america phrma trade industry group member marketing advertising practice european union eu include scheringplough key market united kingdom france germany italy regulation local country level additional regulation eu level european medicine agency emea pharmaceutical product regulate level national mutual recognition centralized regulatory procedure emea coordinate evaluation supervision medicinal product eu paneu market pricing system individual member state systemsagencie regulate price local level japan regulation pharmaceutical medical device agency pmda pmda regulate pharmaceutical medical device development post marketing use japanese government regulate pricingreimbursement pharmaceutical product japan complicated pricing process include benchmark price western country canada select eu country major country influence pricing cms united states increase pressure pharmaceutical industry bring product market provide differentiation versus exist product lead expensive scientifically challenging clinical trial order generate type datum new product versus market comparator raw material raw material essential scheringploughs operation available adequate quantity number potential supplier energy expect available scheringplough sufficient quantity meet operating requirement seasonality certain scheringplough product particularly respiratory sun care category seasonal nature seasonal pattern pronounce effect consolidated operation scheringplough table content environment date compliance federal state local law discharge material environment protection environment material effect schering plough capital expenditure earning competitive position employee december scheringplough employ approximately people worldwide available information scheringplough ks qs ks amendment report file furnish sec available free charge scheringplough website soon reasonably practicable material electronically file sec scheringploughs address world wide web wwwscheringploughcom scheringplough begin practice quarter report available scheringplough website hour filing report file scheringplough sec read copy secs public reference room f street ne washington dc information operation public reference room obtain call sec sec sec maintain internet site wwwsecgov contain report proxy information statement information issuer file electronically sec item risk factor scheringplough future operating result cash flow differ materially result describe k risk uncertaintie relate scheringploughs business include discuss addition factor represent risk uncertainty cause actual result differ materially imply forwardlooke statement contain report key scheringplough product generate significant scheringplough profit cash flow event adversely affect market lead product material negative impact result operation cash flow scheringplough ability generate profit operate cash flow largely dependent continue profitability scheringplough cholesterol franchise consist vytorin zetia addition product pegintron rebetol remicade temodar otc claritin nasonex account material portion revenue result scheringploughs dependence key product event adversely affect market product significant impact result operation event include loss patent protection increase cost associate manufacturing otc availability scheringplough product competitive product discovery previously unknown effect increase competition introduction new effective treatment discontinuation removal market product reason example profitability scheringplough cholesterol franchise adversely affect introduction multiple generic form december compete cholesterol product lose patent protection early year recent year market pegintron rebetol adversely affect result introduction competitor product pegylate interferon introduction generic ribavirin value pegintron pegylate interferon rebetol ribavirin combination therapy hepatitis severely diminish earning cash flow materially negatively impact high risk fund invest research generate financial return development novel drug require significant expenditure low probability success high rate failure inherent research develop new drug treat disease result high risk fund invest research program generate financial return risk profile table content compound fact research long investment cycle bring pharmaceutical compound discovery phase market decade failure occur point process include later process significant fund invest scheringplough success dependent development marketing new product uncertaintie regulatory approval process result failure product reach market product appear promise development fail reach market numerous reason include follow finding ineffectiveness superior safety efficacy compete product harmful effect clinical preclinical testing failure receive necessary regulatory approval include delay approval new product new indication lack economic feasibility manufacturing cost factor preclusion commercialization proprietary right intellectual property protection innovation important contributor scheringplough profitability generic form scheringplough product introduce market result expiration patent cover scheringploughs product successful challenge scheringplough patent atrisk launch generic version scheringplough product material negative effect result operation intellectual property protection critical scheringplough ability successfully commercialize product expiration successful challenge scheringplough patent cover product competitor introduce lowerpriced generic version product include scheringplough wellestablishe product recent year generic manufacturer launch generic version product ultimate resolution patent litigation commonly know atrisk product launch generic competition result loss significant portion sale downward pressure price scheringplough offer patent product particularly patent patent application relate scheringplough significant product material importance scheringplough additionally certain foreign government indicate compulsory license patent grant case national emergency diminish eliminate sale profit region negatively affect scheringploughs result operation patent dispute costly prosecute defend adverse judgment result damage award increase royalty similar payment decrease sale patent position highly uncertain patent dispute pharmaceutical industry unusual adverse result patent dispute involve scheringploughs patent patent collaborator lead loss market exclusivity render patent invalid adverse result patent dispute involve patent hold party preclude commercialization scheringplough product force scheringplough obtain license order continue manufacture marketing affect product license available commercially reasonable term negatively affect sale exist product result injunctive relief payment financial remedy example scheringploughs product dr scholl freeze away wart removal product currently subject patent infringement action bring party company adverse outcome action result scheringplough inability continue manufacture product scheringplough ultimately successful particular dispute scheringplough incur substantial cost defend patent intellectual property right example generic manufacturer file abbreviate new drug application seek approval expiration applicable datum exclusivity allege patent list innovator new drug table content application invalid infringe allegation commonly know paragraph iv certification innovator ability file suit generic manufacturer enforce patent recent year generic manufacturer paragraph iv certification extensively challenge patent wide array innovative pharmaceutical anticipate trend continue potential litigation scheringploughs intellectual property right exist initiate party attempt abridge scheringplough right scheringplough protect right patent challenge hatchwaxman act item business discussion current paragraph iv certification scheringplough product foreign regulation include establish scheringploughs ability price product negatively affect scheringplough sale profit margin scheringplough face increase pricing pressure abroad manage care organization institution government agency program negatively affect scheringplough sale profit margin example medicare prescription drug improvement modernization act contain prescription drug benefit individual eligible medicare prescription drug benefit effective january result increase use generic increase purchasing power negotiating behalf medicare recipient addition legislation concern price control trend affect scheringplough business include legislative regulatory action relate pharmaceutical pricing reimbursement health care reform initiative drug importation legislation involuntary approval medicine otc use consolidation customer trend manage care health care cost containment result government effort reduce medicaid expense manage care organization continue grow influence scheringplough face increase pricing pressure manage care organization continue seek price discount respect scheringplough product outside governmental agency strictly control directly indirectly price pharmaceutical product sell international market cost control method include restriction physician prescription level patient reimbursement emphasis great use generic drug acrosstheboard price cut decrease revenue internationally material pende government investigation scheringplough lead commencement civil andor criminal proceeding involve imposition substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program rise investigation litigation government entity private party scheringplough predict certainty outcome pende investigation subject lead judgment settlement involve significant monetary award restriction operation pricing sale marketing program arrangement relate business practice scheringplough participant health care industry increase scrutiny federal state regulatory investigative prosecutorial administrative entity entity include department justice attorney office office inspector general department health human service fda federal trade commission state attorney general office health care law certain governmental entity operate include federal state antikickback statute statutory common law false claim law construe broadly court permit government entity exercise significant discretion event governmental entity believe wrongdoing occur institute civil criminal proceeding resolve unfavorably subject scheringplough substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program addition adverse outcome government investigation prompt government entity commence investigation scheringplough cause entity private party bring civil claim scheringplough predict table content investigation affect marketing practice sale result material adverse impact scheringplough result operation cash flow financial condition business regardless merit outcome investigation government investigation costly divert management attention scheringplough business result substantial damage scheringplough reputation refer item legal proceeding description pende investigation legal matter adverse outcome negatively affect scheringplough business unfavorable outcome pende litigation matter future litigation include litigation concern product pricing security law violation product liability claim erisa matter patent intellectual property dispute antitrust matter preclude commercialization product negatively affect profitability exist product subject scheringplough substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program result materially adversely affect scheringploughs result operation cash flow financial condition business refer item legal proceeding description significant pende litigation scheringplough subject governmental regulation failure comply cost compliance regulation adversely affect scheringplough financial position result operation scheringplough manufacture facility clinicalresearch practice meet stringent regulatory standard subject regular inspection cost regulatory compliance include associate compliance failure materially affect scheringploughs financial position result operation failure comply regulation include pharmacovigilance reporting requirement standard relate clinical laboratory manufacturing practice result delay approval drug seizure recall drug suspension revocation authority necessary production sale drug fine civil criminal sanction example scheringplough agree fda entry consent decree resolve issue relate compliance current good manufacturing practice certain scheringploughs facilities new jersey puerto rico consent decree work place significant additional control production release product site increase cost slow production lead reduction number product produce site scheringplough research development operation negatively impact consent decree operation share common facility manufacturing operation scheringplough subject regulation include environmental health safety labor regulation development follow regulatory approval decrease demand scheringplough product product reaches market certain development follow regulatory approval include result postmarkete phase iv trial decrease demand scheringplough product include follow rereview product market new scientific information evolution scientific theory recall loss marketing approval product market uncertainty concern safety labeling change great scrutiny advertising promotion table content past year clinical trial postmarkete surveillance certain market drug competitor industry raise safety concern lead recall withdrawal adverse labeling market product situation raise concern prescriber patient relate safety efficacy pharmaceutical product general negatively affect sale product addition follow wake recent product withdrawal company significant safety issue health authority fda european medicine agency pharmaceutical medicine device agency increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication rereviewe select product market add uncertainty regulatory process great regulatory scrutiny especially advertising promotion particular directtoconsumer advertising previously unknown effect discover increase prevalence negative publicity know effect scheringplough product significantly reduce demand product require scheringplough remove product market current environment pharmaceutical company operate scheringplough risk product liability claim product new product technological advance develop scheringploughs competitor negatively affect sale scheringplough operate highly competitive industry scheringplough compete large number multinational pharmaceutical company biotechnology company generic pharmaceutical company scheringploughs competitor conduct research development area serve scheringplough current product product scheringplough process develop competitive development impact scheringplough include technological advance patent grant new product develop competitor new exist generic prescription andor otc product compete product scheringplough merckscheringplough cholesterol partnership addition possible doctor patient provider favor product offer competitor safety efficacy pricing reimbursement characteristic result scheringplough unable maintain sale product competition party difficult scheringplough acquire license new product product candidate regardless stage development enter transaction term permit scheringplough generate positive financial impact scheringplough depend acquisition inlicense arrangement source new product opportunity obtain license new product limit secure right typically require substantial amount fund substantial resource commitment scheringplough compete opportunitie company party great financial resource great ability resource commitment scheringplough able acquire license new product adversely impact scheringplough prospect scheringplough difficulty acquire license new product acceptable term secure right new product schere plough substantial financial resource commitment limit ability produce positive financial impact transaction scheringplough rely thirdparty relationship key product conduct change circumstance party adversely impact business scheringplough relationship party scheringplough depend key product party compete scheringplough interest align interest scheringplough notwithstanding contract scheringplough party table content scheringplough able control influence conduct party circumstance affect adversely impact scheringplough scheringplough operate global business expose scheringplough additional risk adverse event material negative impact result operation scheringplough operate country nonus operation generate majority scheringplough profit cash flow nonus operation subject certain risk inherent conduct business overseas risk include change foreign medical reimbursement policy program price restriction multiple foreign regulatory requirement restrict scheringploughs ability manufacture sell product fluctuation inflation interest rate foreign currency exchange rate trade protection measure import export licensing requirement diminish protection intellectual property country possible nationalization expropriation addition change scheringplough business political position instability disruption destruction significant geographic region regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease insurance coverage product liability unavailable cost prohibitive scheringplough maintain insurance coverage deductible selfinsurance reflect market condition include cost availability exist time write relationship insurance coverage selfinsurance vary accordingly result increase product liability claim pharmaceutical industry availability party insurance unavailable cost prohibitive scheringplough subject evolve complex tax law result additional liability affect result operation scheringplough subject evolve complex tax law foreign jurisdiction significant judgment require determine scheringploughs tax liability scheringplough tax return periodically examine tax authority scheringplough federal income tax return period currently audit internal revenue service scheringplough challenge irs tax authority position take income tax return scheringplough believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority complexity tax contingency ultimate resolution tax matter result payment great amount accrue addition scheringplough impact change tax law include tax rate change change law relate remittance foreign earning new tax law revise tax law interpretation domestic foreign jurisdiction item b unresolved staff comment table content item property scheringplough corporate headquarters locate kenilworth new jersey principal research facility locate kenilworth union summit new jersey palo alto california cambridge massachusetts elkhorn nebraska principal manufacturing facility follow location product type belgium pharmaceuticals cleveland tennessee usa consumer products ireland pharmaceutical consumer product animal health kenilworth new jersey usa pharmaceuticals consumer product mexico pharmaceuticals omaha nebraska usa animal health puerto rico pharmaceuticals singapore pharmaceuticals scheringplough own property exception massachusetts research facility general property adequately maintain suitable purpose discuss detail ii k certain scheringplough manufacturing site operate capacity scheringplough take action streamline manufacturing operation continue work enhance longterm competitiveness item management discussion analysis note special charge manufacture streamline note consent decree item financial statement supplementary datum additional information scheringplough currently process build pharmaceutical sciences center new jersey capital expenditure approximately million related center additional capital expenditure approximately million expect year scheringplough upgrade process system strengthen talent rd area item legal proceeding material pende legal proceeding ordinary routine litigation incidental business scheringplough corporation subsidiary property subject disclose additional information legal proceeding include important financial information find litigation charge discussion note special charge manufacture streamline item management discussion analysis note legal environmental regulatory matter contain item financial statement supplementary datum patent matter describe patent trademark intellectual property right item business intellectual property protection critical scheringplough ability successfully commercialize product innovation potential litigation scheringploughs intellectual property right exist initiate party attempt abridge scheringplough right scheringplough protect right patent matter describe potential material effect scheringplough dr scholl freeze away patent july orasure technology file action district court eastern district pennsylvania allege patent infringement scheringplough healthcare product sale dr scholl freeze away wart removal product complaint seek permanent injunction unspecified damage include treble damage table content massachusetts investigation august scheringplough announce reach agreement attorney office district massachusetts settle investigation involve schering plough sale marketing clinical trial practice program warrick pharmaceuticals warrick scheringploughs generic subsidiary massachusetts investigation investigation focus follow allege practice provide remuneration manage care organization physician induce purchase schering pharmaceutical product offlabel marketing drug submit false pharmaceutical pricing information government purpose calculate rebate require pay medicaid program agreement provide aggregate settlement million criminal fine million million resolve civil aspect investigation january schere sale corporation subsidiary scheringplough plead guilty count conspiracy false statement government connection settlement scheringplough sign addendum exist corporate integrity agreement office inspector general department health human service addendum affect schering plough ongoing business customer include federal government scheringplough record liability million relate massachusetts investigation investigation state litigation describe awp litigation investigation settlement million relate massachusetts investigation awp litigation investigation ongoing awp litigation investigation scheringplough continues respond exist new litigation certain state private payor investigation department health human services department justice state industry scheringplough practice average wholesale price awp scheringplough cooperating investigation litigation investigation relate awp pharmaceutical company certain drug improperly exceed average price pay provider consequence result unlawful inflation certain reimbursement drug state program private payor base awp complaint allege violation federal state law include fraud medicaid fraud consumer protection violation claim majority case plaintiff seek class certification case class certify outcome litigation investigation include substantial damage imposition substantial fine penalty injunctive administrative remedy security class action litigation federal security litigation follow scheringploughs announcement fda conduct inspection scheringplough manufacture facility new jersey puerto rico issue report cite deficiency concern compliance current good manufacturing practice lawsuit file scheringplough certain name officer lawsuit allege defendant violate federal security law allegedly fail disclose material information make material misstatement specifically allege scheringplough fail disclose allege risk new drug application clarinex delay result manufacturing issue allege scheringplough fail disclose allege depth severity manufacturing issue complaint consolidate action district court district new jersey consolidated amend complaint file october purport represent class shareholder purchase share scheringplough stock february complaint seek compensatory damage behalf class court certify shareholder class october discovery ongoing table content shareholder derivative action lawsuit file district court district new jersey scheringplough certain officer director director seek damage behalf scheringplough include disgorgement trading profit defendant allegedly obtain basis material nonpublic information complaint allege failure disclose material information breach fiduciary duty director relate fda inspection investigation scheringplough pricing practice sale marketing clinical trial practice lawsuit shareholder derivative action purport assert claim behalf scheringplough shareholder derivative action pende district court district new jersey consolidate action august erisa litigation march scheringplough serve putative class action complaint file district court new jersey allege scheringplough retire chairman ceo president richard jay kogan scheringploughs employee saving plan plan administrator current director certain corporate officer messrs larosa moore breach fiduciary obligation certain participant plan complaint seek damage loss allegedly suffer plan complaint dismiss june plaintiff appeal august court appeal circuit reverse dismissal district court matter remand district court proceeding kdur antitrust litigation scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle relate generic version kdur scheringploughs longacte potassium chloride product supplement cardiac patient lederle upsher smith file abbreviate new drug application follow commencement ftc administrative proceeding allege anticompetitive effect settlement allege class action suit file federal state court behalf direct indirect purchaser k dur scheringplough upshersmith lederle suit claim violation federal state antitrust law state statutory common law cause action suit seek unspecified damage discovery ongoing thirdparty payor action purport class action litigation file follow announcement settlement massachusetts investigation plaintiff action seek damage behalf thirdparty payor result allegation offlabel promotion improper payment physician issue massachusetts investigation tax matter october irs auditor assert interest rate swap scheringplough enter unrelated party recharacterize loan affiliate company result additional tax liability tax year september scheringplough payment irs million income tax million interest scheringplough file refund claim tax interest irs december follow irss denial scheringplough claim refund scheringplough file suit district court district new jersey refund tax interest refund litigation currently discovery phase scheringplough tax reserve adequate cover abovementione payment pende administrative obligation connection settlement investigation department justice attorney office eastern district pennsylvania scheringplough enter fiveyear corporate integrity agreement cia cia amend august connection table content settlement massachusetts investigation commence new fiveyear term disclose note consent decree scheringplough subject obligation consent decree fda failure comply obligation cia consent decree result financial penalty discussion pende pharmacovigilance matter result pharmacovigilance inspection official british french medicine agency conduct request european medicine agency emea refer regulatory competitive environment scheringplough operate item management discussion analysis matter nitrodur investigation august scheringplough receive civil investigative subpoena issue office inspector general department health human service seek document concern scheringplough classification nitrodur medicaid rebate purpose scheringploughs use nominal pricing bundle product sale scheringplough cooperate investigation appear subpoena number address pharmaceutical company concern inquiry issue relate payment government rebate senate finance committee inquiry january united states senate committee finance follow previous request scheringplough request information scheringplough practice relate educational grant scheringplough understand committee direct similar followup request pharmaceutical company scheringplough cooperate committee respond request french matter base complaint french competition authority competitor france pursuant court order french competition authority obtain document french subsidiary scheringplough relate product subsidiary market sell resolution matter adverse french subsidiary result imposition civil fine injunctive administrative remedy item submission matter vote security holder applicable table content executive officer registrant list executive officer corporate officer scheringplough february indicate hold position indicate past year officer serve year successor duly appoint title ag e robert j bertolini executive vice president chief financial officer john carroll vice president global internal audits c ron cheeley senior vice president global human resource carrie cox executive vice president president global pharmaceuticals william j creelman vice president tax fred hassan chairman chief executive officer steven h koehler vice president controller thomas p koestler phd executive vice president president scheringplough research institute raul e kohan senior vice president president animal health joseph j larosa vice president legal affair ian mcinne senior vice president global supply chain e kevin moore vice president treasurer lori queisser senior vice president global compliance business practice thomas j sabatino jr executive vice president general counsel karl salnoske vice president chief information officer brent saunder senior vice president president consumer health care susan ellen wolf corporate secretary associate general counsel vice president corporate governance officer define rule af securities exchange act mr bertolini join scheringplough executive vice president chief financial officer mr bertolini partner pricewaterhousecoopers mr carroll join scheringplough vice president global internal audits mr carroll vice president general auditor american standard company general auditor american standard company assistant treasurer bristolmyer squibb mr cheeley join scheringplough senior vice president global human resources mr cheeley group vice president global compensation benefit pharmacia corporation ms cox join scheringplough executive vice president president global pharmaceuticals ms cox executive vice president president global prescription business pharmacia corporation mr creelman join scheringplough vice president tax mr creelman senior tax counsel pfizer mr creelman assistant vice president international tax cigna corporation mr hassan join scheringplough chairman board chief executive officer mr hassan chairman board chief executive officer pharmacia corporation table content mr koehler join scheringplough vice president controller mr koehler senior vice president chief financial officer treasurer vice president chief financial officer treasurer corporate secretary medicine company dr koestler name executive president president scheringplough research institute september dr koestler executive vice president global development scheringplough research institute september executive vice president scheringplough research institute senior vice president global regulatory affair pharmacia corporation mr kohan name senior vice president president animal health february mr kohan appoint president scheringplough animal health group head specialty operation mr larosa vice president legal affair mr larosa staff vice president secretary associate general counsel dr mcinne join scheringplough senior vice president global supply chain dr mcinne executive vice president supply chain watson pharmaceuticals inc senior vice president global supply chain pharmacia corporation ms queisser join scheringplough february senior vice president global compliance business practice ms queisser vice president chief compliance officer october february executive director general auditor march october eli lilly company mr sabatino join scheringplough executive vice president general counsel mr sabatino senior vice president general counsel baxter international inc mr salnoske join scheringplough vice president chief information officer mr salnoske ceo adaptive trade mr saunder appoint senior vice president president consumer health care february mr saunder join scheringplough senior vice president global compliance business practice mr saunders partner pricewaterhousecooper ms wolf name vice president corporate secretary associate general counsel hold position scheringplough law department table content ii item market registrant common equity relate stockholder matter principal market scheringplough common stock new york stock exchange additional information require item incorporate reference table caption quarterly datum unaudite item financial statement supplementary datum follow table provide information respect purchase scheringplough common share fourth quarter issuer purchase equity security total number maximum number share purchase share average publicly purchase total number price pay announce plan plan period share purchase share program programs october october na na november november na na december december na na total october december na na share include table repurchase pursuant scheringploughs stock incentive program represent share deliver scheringplough option holder payment exercise price tax withholding obligation connection stock option stock award table content performance graph comparison cumulative total return year end december scheringplough corporation composite peer group sp index graph assume investment december reinvestment dividend scheringplough common share sp index composite peer group major usbased pharmaceutical company abbott laboratories bristolmyers squibb company johnson johnson eli lilly company merck co inc pfizer inc wyeth warner lambert company pharmacia corporation long publicly trade acquire pfizer inc long include peer index table content item select financial datum million share figure percentage operate result net sale equity income cholesterol joint venture incomeloss income taxis net incomeloss net incomeloss available common shareholder dilute earningsloss common share basic earningsloss common share research development expense depreciation amortization expense financial position cash flow property net total asset longterm debt shareholder equity capital expenditure financial statistic net incomeloss percent net sale return average shareholder equity net book value common share datum cash dividend common share cash dividend pay common share cash dividend prefer share average share outstanding calculate dilute earningsloss common share average share outstanding calculate basic earningsloss common share common share outstanding yearend include special charge manufacture streamlining cost respectively note special charge manufacture streamline additional information charge incur special charge incur include increase litigation reserve million million respectively result investigation scheringplough sale marketing practice special charge include approximately million employee termination cost relate voluntary early retirement program announce august million asset impairment charge relate closure manufacturing facility united kingdom writedown production equipment relate product long go produce manufacturing site operate fda consent decree writedown drug license sun care trade expect cash flow support carry value assume conversion prefer share approximately million common share million common share million common share table content item management discussion analysis financial condition result operation executive summary overview scheringplough scheringplough discover develop manufacture market medical therapy treatment enhance human health scheringplough market lead consumer brand overthecounter otc foot care sun care market operate global animal health business source new product product acquire acquisition licensing arrangement product scheringploughs latestage research pipeline respect acquisition license scheringplough recently acquire new product license limit opportunity obtain license critical latestage product positive material financial impact limit opportunity typically require substantial amount fund scheringplough compete opportunity company great financial resource strategy focus science early decade scheringplough experienced number business regulatory legal challenge april board director name fred hassan new chairman board chief executive officer scheringplough corporation support board recruit new senior executive team initiate strategic plan goal stabilize repair turn scheringplough order build longterm shareholder value strategic plan action agenda eightyear fivephase plan october scheringplough announce enter fourth phase action agenda build base build base phase scheringplough continue focus strategy value creation broad include grow business penetrate new market expand exist product discover develop acquire new product effort scheringplough enhance infrastructure upgrading process system strengthen talentboth recruitment talented individual development key employee effort companywide scheringplough focus especially research development key component action agenda apply science meet unmet medical need research development activity focus mechanism treat disease result core strategy scheringplough invest substantial fund scientific research goal create therapy treatment important medical commercial value consistent core strategy scheringplough increase investment research development scheringplough progress pipeline include drug candidate wide range therapeutic area compound approach phase development scheringplough continue develop late phase growthdriver pipeline eg thrombin receptor antagonist golimumab vicriviroc hcv protease inhibitor anticipate high spending clinical trial activity result highlight scheringplough performance follow scheringplough net sale billion increase billion percent compare period net income available common shareholder billion compare million cash flow operating activity billion global sale scheringplough cholesterol franchise product vytorin zetia cholesterol joint venture merck company inc merck continue grow significantly contribute scheringplough improve operating result cash flow addition increase sale table content pharmaceutical product remicade nasonex temodar clarinex contribute favorably scheringplough overall operating result cash flow scheringplough gain approval new product indication include lifesave antifungal medicine noxafil oral suspension united states eu prevention invasive fungal infection noxafil discover scheringploughs research laboratory temodal japan treatment form brain cancer malignant glioma remicade eu ulcerative colitis suboxone sublingual tablet eu opioid dependence scheringplough streamlined global supply chain yield expect annualize cost saving million scheringplough reach agreement attorney office district massachusetts department justice settle previously disclose investigation relate action take place prior agreement provide aggregate settlement million settlement material adverse effect scheringploughs result operation financial condition business strategic alliance typical pharmaceutical industry scheringplough license manufacturing marketing andor distribution right certain product manufacture market andor distribute product own pursuant license joint venture arrangement time party involve additional factor relate party outside control scheringplough create positive negative impact scheringplough vytorin zetia remicade subject arrangement key scheringplough current business financial performance addition potential strategic alternative impact change control provision arrangement result vytorin zetia acquire merck remicade revert centocor change control provision relate vytorin zetia include contract merck file exhibit r scheringploughs k change control provision relate remicade contain contract centocor file exhibit v scheringploughs k cholesterol franchise scheringploughs cholesterol franchise product vytorin zetia manage joint venture scheringplough merck treatment elevated cholesterol level zetia scheringplough novel cholesterol absorption inhibitor vytorin combination zetia zocor mercks statin medication financial commitment compete cholesterol reduction market share merck profit sale vytorin zetia share merck operating result joint venture merck record equity method accounting material change sale market share scheringplough cholesterol franchise significant impact scheringplough result operation cash flow order maintain enhance infrastructure business scheringplough continue increase profit increase profitability largely dependent performance schering plough cholesterol franchise cholesterolreduction market single large pharmaceutical category world vytorin zetia compete market combine basis product continue grow term market share franchise product capture percent total prescription cholesterol management market base january ims datum japan include joint venture merck japanese market bayer healthcare comarket scheringploughs cholesterolabsorption inhibitor zetia approval scheringplough anticipate receive approval japan backlog new drug application japan scheringplough precisely predict timing approval table content license arrangement centocor remicade prescribe treatment immunemediate inflammatory disorder rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylose spondylitis plaque psoriasis ulcerative colitis remicade scheringplough second large market pharmaceutical product line cholesterol franchise remicade license manufactured centocor inc johnson johnson company scheringplough exclusive marketing right product outside japan certain asian market scheringplough exercise option contract centocor license right develop commercialize golimumab new tnfalpha monoclonal antibody territory remicade golimumab currently phase iii trial scheringplough centocor collaborate resolve difference party opinion expiration date scheringplough right golimumab august scheringplough receive determination arbitration right market golimumab extend year commercial sale territory centocor appeal rule manufacturing sale marketing scheringplough support commercialize product manufacturing sale marketing effort scheringplough move forward additional investment enhance infrastructure business include capital expenditure drug development process product move drug discovery pipeline market information technology system postmarkete study monitor scheringplough continually review business include manufacturing operation identify action enhance longterm competitiveness scheringplough manufacturing cost base relatively fix action significantly reduce scheringploughs manufacturing infrastructure involve complex issue result shift product manufacturing plant year construction regulatory requirement include revalidation registration requirement scheringplough close manufacturing plant take streamlining action scheringplough continue review carry value manufacture asset indication impairment future event decision lead additional asset impairment relate cost regulatory competitive environment scheringplough subject jurisdiction national state local regulatory agency regulatory compliance complex costly impact timing need bring new drug market market drug new indication scheringplough work fda consent decree resolve issue involve scheringploughs compliance current good manufacturing practice certain manufacturing site new jersey puerto rico term decree provide fda notify scheringplough significant violation fda law regulation decree fiveyear period decree entry scheringplough petition court decree dissolve fda oppose scheringploughs petition assurance particular date consent decree lift scheringplough subject pharmacovigilance reporting requirement country jurisdiction include eu eumember states scheringplough engage clinical trial research country world research activity comply stringent regulatory standard subject inspection eu local country regulatory authority clinical trial postmarkete surveillance certain market drug competitor industry raise safety concern lead recall withdrawal adverse labeling market product pricing sale marketing program arrangement relate business practice scheringplough participant health care industry increase scrutiny federal state regulatory investigative prosecutorial administrative entity table content scheringploughs pharmaceutical product subject increasingly competitive pricing manage care group institutions government agency group seek price discount international market scheringplough operate environment government mandate costcontainment program market pharmaceutical product competitive scheringplough operation affect technological advance competitor industry consolidation patent grant competitor loss patent protection challenge competitor competitive combination product new product competitor new information clinical trial market product postmarkete surveillance generic competition scheringplough product mature discussion operating result net sale significant portion net sale major pharmaceutical health care product distributor major retail chain consequently net sale quarterly growth comparison affect fluctuation buy pattern major distributor retail chain trade buyer fluctuation result seasonality pricing wholesaler buying decision factor addition fluctuation sale pharmaceutical product subject increase pricing pressure manage care group institution government agency group seek discount scheringplough pharmaceutical manufacturer market require provide statutorily define rebate government agency order participate medicaid program veterans health care program governmentfunde program international market scheringplough operate environment government mandate costcontainment program place restriction physician prescription level patient reimbursement emphasize great use generic drug enact acrosstheboard price cut method control cost consolidate net sale billion increase billion percent compare increase primarily reflect growth sale volume remicade nasonex pegintron temodar increase reflect unfavorable impact percent foreign exchange consolidated net sale total billion increase billion percent compare reflect high volume remicade nasonex pegintron temodar inclusion year sale avelox cipro addition foreign exchange favorable impact percent table content net sale year end december follow incr e e decre ase dollar million prescription pharmaceutical remicade nasonex pegintron clarinexaerius temodar claritin rx integrilin rebetol avelox nm intron caelyx subutex elocon cipro nm pharmaceutical consumer health care otc nm foot care sun care animal health consolidate net sale nm meaningful percentage international net sale remicade drug treatment immunemediate inflammatory disorder rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylose spondylitis plaque psoriasis ulcerative colitis percent billion compare percent million compare great demand expand indication continue market growth competitive product indication refer introduce additional competitive product expect introduce global net sale nasonex nasal spray oncedaily corticosteroid nasal spray allergy rise percent million compare percent million compare product capture great international market share sale benefit increase promotional effort introduction new scentfree alcoholfree formulation nasonex nasal spray generic form flonase fluticasone propionate approve early unfavorably impact corticosteroid nasal spray market go forward global net sale pegintron powder injection pegylate interferon product treat hepatitis c increase percent million compare percent million compare sale increase reflect high sale volume japan sale growth december launch peg intron rebetol combination therapy japan japan sale benefit significant number patient wait approval pegintron begin treatment pegintron sale japan begin decline end table content trend expect continue new patient enrollment hepatitis c treatment moderate new competition enter japanese market global net sale clarinex market aerius country outside treatment seasonal outdoor allergy yearround indoor allergy increase percent million compare increase demand europe latin america increase sale despite slightly decline market share global net sale clarinex decrease percent million compare primarily reduced market share decline market global net sale temodar capsule treatment certain type brain tumor increase percent million compare increase percent million compare increase sale increase utilization new indication temodar approve fda treat newly diagnose glioblastoma multiforme gbm prevalent form brain cancer european commission use combination radiotherapy gbm patient eumember state iceland norway temodar approve japan treatment malignant glioma growth rate temodar expect moderate significant market penetration achieve treatment gbm international net sale prescription claritin decrease percent million compare sale increase percent million compare launch claritin reditab japan couple unusually severe japanese allergy season global net sale integrilin injection glycoprotein platelet aggregation inhibitor treatment patient acute coronary syndrome sell primarily scheringplough increase percent million compare sale decrease percent million compare effective september scheringplough restructure integrilin copromotion agreement millennium term restructure agreement scheringplough acquire exclusive development commercialization right integrilin exchange upfront payment million royalty integrilin sale restructure agreement call minimum royalty payment million year millennium global net sale rebetol capsule use combination pegintron intron treat hepatitis c decrease percent million compare low sale europe increase competition global net sale increase percent million compare primarily launch pegintron rebetol combination therapy japan december japan sale benefit significant number patient wait approval pegintron begin hepatitis c treatment sale expect continue decline result moderation hepatitis c patient enrollment japan new competition enter japanese market net sale avelox fluoroquinolone antibiotic treatment certain respiratory skin infection sell primarily scheringplough result license agreement bayer increase percent million compare million share growth new indication sale avelox represent initial month sale agreement bayer effective october global net sale intron injection chronic hepatitis b c antiviral anticancer indication decrease percent million compare percent million compare conversion pegintron treat hepatitis c japan international net sale caelyx treatment ovarian cancer metastatic breast cancer kaposis sarcoma increase percent million compare primarily expand market product sale increase percent million compare reflect adoption ovarian cancer metastatic breast cancer indication international net sale subutex tablet treatment opiate addiction increase percent million compare increase market share sale increase percent million table content compare increase market penetration october suboxone approve eu include member state iceland norway treatment opioid dependence global net sale elocon cream mediumpotency topical steroid decrease percent million compare decrease percent million compare reflect generic competition introduce quarter generic competition expect continue adversely affect sale product net sale cipro fluoroquinolone antibiotic treatment certain respiratory skin urinary tract infection sell primarily scheringplough result license agreement bayer decrease percent million compare million market share erosion generic competition sale cipro represent initial month sale agreement bayer pharmaceutical net sale include large number low sale volume prescription pharmaceutical product product sell limited market outside multiple source product long protect patent product include treatment respiratory cardiovascular dermatological infectious oncological disease include pharmaceutical sale sale scheringplough albuterol product fda issue final rule require cfc albuterol product include scheringplough proventil cfc remove market later december scheringplough manufacturer albuterol cfc transition albuterol hfa proventil hfa prior yearend deadline scheringplough begin transition hfa product scheringplough uncertain ultimate impact scheringplough overall future sale proventil product complexity multiple external factor influence transition include compete albuterol hfa product global net sale consumer health care product include otc foot care sun care product increase percent million compare reflect increase sale sun care product dr scholl foot care product sale billion sale otc claritin decrease percent million compare percent million compare result restriction retail sale otc product contain pseudoephedrine pse addition otc claritin continue face competition private label brand loratadine net sale sun care product increase million percent compare million percent compare primarily success new coppertone continuous spray product launch sale sun care product reflect strong overall suncare season future sale difficult predict consumer health care market highly competitive heavy advertising consumer frequent competitive product introduction global net sale animal health product increase percent million compare percent million compare reflect strong growth core brand geographic specie area lead high sale companion animal product product serve cattle market include nuflor vaccine business lead sale growth increase net sale well product supply scheringplough expect growth rate moderate increase competition include introduction generic product table content cost expense equity income summary cost expense equity income year end december follows incre e decr ease dollar million gross margin sell general administrative sga research development rd incomeexpense net nm nm special charge nm nm equity income cholesterol joint venture nm nm nm meaningful percentage substantially sale cholesterol product include scheringplough net sale result sale reflect equity income cholesterol joint venture addition virtual nature joint venture scheringplough incur substantial sell general administrative expense capture equity income include scheringploughs statement consolidated operation result scheringplough gross margin ratio sga expense rd expense percentage net sale reflect benefit impact joint venture operate result gross margin despite negative impact cost sale cost result scheringplough action streamline manufacturing operation gross margin increase percent percent improvement gross margin primarily increase sale high margin product process improvement scheringploughs supply chain include cost saving manufacturing streamlining activity complete cost sale include charge total million associate schering plough action streamline manufacturing operation offset saving approximately million result action note special charge manufacture streamline item financial statement supplemental datum additional information gross margin increase percent percent primarily supply chain process improvement increase sale highermargin product favorable impact foreign exchange partly offset high royalty relate bayer product begin september royalty integrilin sell general administrative selling general administrative expense sga increase percent billion compare reflect ongoing investment emerge market field support product launch high promotional spending sga expense increase percent billion compare billion increase primarily addition fourth quarter bayer sale representative increase selling expense europe support continue launch vytorin zetia increase promotional spending primarily nasonex asmanex product agreement bayer research development research development rd spending increase percent billion compare period rd spending increase percent billion compare period increase high cost associate clinical trial build great breadth capacity support scheringplough progress pipeline increase partially million charge quarter result scheringplough exercise right develop commercialize golimumab rd spending include million charge conjunction license toyama table content chemical company ltd garenoxacin generally change rd spending reflect timing scheringplough fund internal research effort research collaboration partner discover develop steady flow innovative product maximize scheringplough chance successful development new product scheringplough begin development excellence initiative build talent critical mass create uniform level excellence deliver highpriority program rd scheringplough begin global clinical harmonization program maximize globalize quality clinical trial execution pharmacovigilance regulatory process incomeexpense net scheringplough income net million compare expense net million million respectively high interest rate large overall balance cash equivalent shortterm investment special charge manufacture streamlining manufacturing streamline scheringplough implement change manufacture operation puerto rico new jersey streamline global supply chain enhance schering plough longterm competitiveness change result phaseout closure scheringplough manufacturing operation manati puerto rico additional workforce reduction las piedras puerto rico new jersey total action result elimination position scheringplough expect action yield annualize cost saving approximately million special charge special charge relate change scheringploughs manufacturing operation total million charge consist approximately million severance million fix asset impairment cost sale include cost sale approximately million consist million accelerate depreciation million inventory writeoff million charge relate closure scheringplough manufacturing facility manati puerto rico follow table summarize activity reflect consolidated financial statement relate change scheringploughs manufacturing operation complete charge include special total cash noncash accrue cost sale charge charge payment charge liability dollar millions accrue liability january severance asset impairment accelerate depreciation inventory writeoff total accrue liability december accrue liability balance december expect pay quarter scheringplough expect incur material additional charge relate manufacturing streamlining action announce table content special charge activity special charge incur follow dollar million litigation charge employee termination cost asset impairment charge litigation charge litigation reserve increase million increase result total reserve million massachusetts investigation investigation state litigation disclose awp litigation investigation note legal environmental regulatory matter represent scheringplough current estimate resolve matter august scheringplough announce reach agreement attorney office district massachusetts department justice settle massachusetts investigation aggregate million plus interest settlement relate massachusetts investigation awp investigation litigation ongoing subsequent december scheringplough payment total million relate settlement include interest million substantially remain payment settlement agreement pay remainder note legal environmental regulatory matter item financial statement supplementary datum additional information employee termination cost august scheringplough announce global workforce reduction initiative phase initiative voluntary early retirement program verp program eligible employee december elect early retirement receive enhance retirement benefit approximately employee elect retire program retire december total cost program approximately million comprise increase pension cost million increase postretirement health care cost million vacation payment million cost relate accelerate vest stock grant million amount recognize program million million respectively additional amount expect recognize program termination cost associate verp total million million respectively follow summarize activity account related employee termination cost employee termination cost dollar million special charge liability balance december special charge incur credit retirement benefit plan liability disbursement special charge liability balance december special charge incur credit retirement benefit plan liability disbursement special charge liability balance december disbursement special charge liability balance december table content asset impairment charge year end december scheringplough recognize asset impairment charge million relate primarily consolidation scheringplough biotechnology organization scheringplough record asset impairment charge million relate primarily shutdown small european research development facility equity income cholesterol joint venture global cholesterol franchise sale include sale vytorin zetia cholesterol joint venture merck scheringplough total billion billion billion respectively sale growth increase market share sale comparison benefit launch vytorin second half franchise product combine capture percent total prescription cholesterol management market base january ims datum scheringplough utilize equity method account joint venture sharing income operation base percentage vary product sale level country scheringplough allocation joint venture income increase milestone earn merck scheringplough partner bear cost general sale force commercial overhead marketing joint venture product world canada puerto rico cholesterol agreement provide reimbursement partner physician detail set annual basis italy contractual include profit sharing calculation reimburse amount equal partner physician detail multiply contractual fix fee scheringplough report amount equity income cholesterol joint venture amount represent specific incremental identifiable cost scheringplough detail cholesterol product market addition amount reflective scheringplough sale effort relate joint venture scheringplough sale force relate cost associate joint venture generally estimate high cost joint venture partner contractually share portion manufacturing cost specifically identify promotion cost include directtoconsumer advertising direct identifiable outofpocket promotion agree cost specific service market support market research market expansion specialty sale force physician education program certain specify research development expense generally share equally partner additional information joint venture merck include note equity income cholesterol joint venture item financial statement supplementary data equity income cholesterol joint venture total billion million million respectively increase equity income compare reflect continue strong sale vytorin zetia equity income comparison benefit launch vytorin second half scheringplough recognize milestone merck million million respectively million milestone relate certain european approval vytorin ezetimibesimvastatin million milestone relate approval ezetimibesimvastatin mexico certain condition specify joint venture agreement merck scheringplough earn additional milestone total million note scheringplough incur substantial sell general administrative cost reflect equity income cholesterol joint venture instead include overall cost structure scheringplough provision income taxis tax expense million million million respectively tax provision include benefit relate operating loss scheringplough establish valuation allowance net defer tax asset include benefit operating loss management conclude likely benefit net defer tax asset realize december scheringplough continue maintain valuation allowance table content defer tax asset scheringplough expect report net operating loss nol carryforward billion tax return year end december nol carryforward materially reduce examination scheringplough income tax return internal revenue service irs scheringplough generate approximately million operating loss difference financial tax reporting expect nol generate tax return operate loss year scheringplough expect continue generate operating loss nol subject difference financial tax reporting income tax provision primarily relate foreign taxis tax provision include benefit million related irs notice issue august result reduction previously accrue tax liability attributable repatriation american job creation act ajca tax provision include million charge relate intended ajca repatriation take place irs examine scheringploughs federal income tax return process complete examination scheringplough anticipate examination complete end finalization irs audit result adjustment scheringplough accrual tax contingency nol report schering plough income tax return scheringplough tax reserve reflect good estimate probable tax liability reasonably possible ultimate resolution tax matter materially great accrue july fasb issue fasb interpretation fin accounting uncertainty income taxis fin prescribe detail guidance financial statement recognition measurement disclosure uncertain tax position recognize enterprise financial statement accordance fasb statement accounting income taxis scheringplough require apply provision interpretation begin january provision fin apply exist uncertain income tax position effective date implementation fin cumulative effect apply provision interpretation report adjustment opening balance schering plough retain earning scheringplough evaluate potential impact fin expect decrease opening retain earning january million million corresponding increase appropriate tax liability account adoption interpretation net incomeloss available common shareholder scheringplough net incomeloss available common shareholder billion million million respectively net income available common shareholder include deduction prefer stock dividend million period relate issuance percent mandatory convertible preferred stock august net loss available common shareholder include deduction prefer stock dividend million net incomeloss available common shareholder include special charge manufacture streamlining cost approximately million million million respectively note special charge manufacture streamline item financial statement supplementary datum additional information addition net income available common shareholder include income item million result cumulative effect change accounting principle net tax relate implementation sfas r sharebase compensation liquidity financial resource discussion cash flow th e ear en de de ce mber dollar million cash flow operating activity cash flow investing activity cash flow financing activity table content operating activity net cash provide operating activity billion increase billion compare increase primarily result high net income timing operate cash payment receipt disclose note legal environment regulatory matter scheringplough reach agreement attorney office district massachusetts department justice settle massachusetts investigation aggregate million plus interest subsequent december scheringplough payment total million relate settlement include interest million substantially remain payment settlement agreement pay remainder operating activity generate million cash compare use million increase primarily high net income timing payment special charge relate litigation partially offset increase account receivable sale growth payment approximately million tax authority tax liability relate repatriation foreign earning ajca tax payment million relate settlement certain tax contingency tax year tax charge relate ajca expense operate cash flow favorably impact tax refund million result loss carryback cash flow unfavorably impact million payment government tax deficiency relate certain transaction tax year payment million settlement agreement attorney office eastern district pennsylvania investing activity net cash investing activity billion primarily relate net purchase shortterm investment billion previously invest cash equivalent million capital expenditure net cash investing activity million primarily relate million capital expenditure purchase intangible asset million partially offset proceed sale property equipment million net reduction shortterm investment million net cash investing activity million include capital expenditure million net purchase investment million partially offset cash proceed million transfer license right million disposition property equipment financing activity net cash financing activity billion million respectively use cash financing activity include payment dividend common prefer share million million respectively repayment billion bank debt shortterm commercial borrowing billion shortterm commercial paper borrowing use cash financing activity partially offset proceed million bank debt incur foreign subsidiary relate funding portion repatriation ajca bank debt fully repay net cash provide financing activity reflect proceed billion preferred stock issuance million increase shortterm borrowing partially offset payment dividend common prefer share million discussion cash flow scheringplough move forward additional investment enhance infrastructure business currently process build pharmaceutical sciences center new jersey capital expenditure approximately million related center additional capital expenditure approximately million expect year center allow scheringplough streamline integrate drug development process product move drug discovery pipeline market additional related expenditure upgrade equipment staffing center table content operation generate negative cash flow operation cash need excess cash generate operation fund dividend payment majority research development cost capital expenditure expect operation generate negative cash flow total cash cash equivalent shortterm investment total debt approximately billion december cash generate operation available cash short term investment expect provide scheringplough ability fund cash need intermediate term percent mandatory convertible preferred stock august scheringplough issue percent mandatory convertible preferred stock receive net proceed billion deducting commission discount underwriting expense proceed reduce shortterm commercial paper borrowing pay tax litigation settlement amount litigation cost fund operating expense capital expenditure prefer stock issue scheringplough billion shelf registration preferred share automatically convert common share scheringplough depend average closing price scheringplough common share period immediately precede mandatory conversion date september define prospectus note shareholder equity item financial statement supplementary datum additional information conversion prefer share trigger cash payment scheringplough december million remain register unissue shelf registration borrowing credit facility november scheringplough issue billion aggregate principal percent senior unsecured note billion aggregate principal percent senior unsecured note proceed offer billion general corporate purpose include repay commercial paper outstanding issuance note rate moodys investor service moodys credit watch negative implication standard poor sp interest rate payable note subject adjustment rating assign note moodys sp downgrade respectively interest rate payable series note increase note shortterm borrowing longterm debt commitment item financial statement supplementary datum additional information july moodys lower rating note baa accordingly interest payable note increase basis point effective december december interest rate payable note increase percent percent interest rate payable note increase percent percent adjustment interest rate payable note increase scheringplough interest expense approximately million annually interest rate payable particular series note return percent percent respectively rate adjustment provision permanently cease apply follow downgrade moodys sp respectively note subsequently rate baa moodys bbb sp scheringplough billion credit facility syndicate bank facility mature require scheringplough maintain total debt total capital ratio percent meet december credit line available general corporate purpose consider support scheringplough commercial paper borrowing borrowing credit facility draw parent company whollyowne international subsidiary accompany parent guarantee facility require compensating balance nominal commitment fee pay december million draw facility whollyowne international subsidiary purpose funding repatriation ajca borrowing fully repay december borrowing outstanding facility addition credit facility scheringplough enter million credit facility fourth quarter purpose funding repatriation ajca december entire draw whollyowne international subsidiary fund repatriation facility pay terminate table content december shortterm borrowing include credit facility mention total million billion respectively include outstanding commercial paper million million respectively weightedaverage interest rate shortterm borrowing december percent percent respectively credit rating scheringplough current unsecured senior credit rating outlook follow senior unsecured credit rating l ongterm shortterm outlook moodys investor service baa p positive standard poor stable fitch rating f stable shortterm rating discuss significantly affect scheringploughs ability issue roll outstanding commercial paper borrowing time scheringplough believe ability commercial paper issuer scheringplough shortterm credit rating p moodys sp andor f fitch issue roll outstanding commercial paper time company high shortterm credit rating addition total commercial paper capacity available issuer typically higherrate company scheringplough sizable line credit commercial bank cash shortterm investment hold international subsidiary serve alternative source liquidity support commercial paper program scheringplough credit rating decline current level impact decline reduce availability commercial paper borrowing increase interest rate scheringplough short longterm debt discuss scheringplough believe exist cash shortterm investment cash generate operation allow scheringplough fund cash need intermediate term contractual obligation offbalance sheet arrangement scheringplough contractual obligation report liability consolidated balance sheet require recognize liability certain purchase commitment executory contract follow table summarize payment period scheringplough know contractual obligation december payman ts p eriod total year year year year dollar million shortterm borrowing current portion longterm debt longterm debt obligation operating lease obligation purchase obligation advertising contract research contract capital expenditure commitment purchase obligation defer compensation plan obligation obligation total longterm debt obligation include million aggregate principal percent senior unsecured note million aggregate principal percent senior unsecured note exclude interest obligation note shortterm borrowing longterm debt table content commitment item financial statement supplementary datum additional information research contract include potential milestone payment payment contingent occurrence certain event table exclude research contract cancelable scheringplough penalty purchase obligation consist cancelable noncancelable inventory expense item caption include obligation base undiscounted amount estimate payment certain scheringplough pension plan prefer stock dividend contractual obligation regulatory competitive environment scheringplough operate scheringplough subject jurisdiction national state local regulatory agency regulation describe detail item business regulatory compliance complex regulatory standard include good clinical practice good laboratory practice good manufacturing practice vary jurisdiction constantly evolve regulatory compliance costly regulatory compliance impact timing need bring new drug market market drug new indication failure comply regulation result delay approval drug seizure recall drug suspension revocation authority necessary production sale drug fine civil criminal sanction regulatory compliance cost compliance failure material impact scheringplough result operation cash flow financial condition unknown science human health drug benefit risk balanced societal government pressure constantly shift demand innovation meet urgent unmet medical need adversity risk pressure impact regulatory environment market scheringplough product regulatory compliance pharmacovigilance consent decree scheringplough work fda consent decree resolve issue involve scheringploughs compliance current good manufacturing practice cgmp certain manufacturing site new jersey puerto rico detail note consent decree item financial statement supplementary datum term consent decree scheringplough payment total million end scheringplough complete revalidation program bulk active pharmaceutical ingredient finish drug product significant step cgmp work plan accordance schedule require consent decree scheringplough obtain thirdparty expert certification completion cgmp work plan require decree certification turn subject acceptance fda term decree provide fda notify scheringplough significant violation fda law regulation decree fiveyear period decree entry scheringplough petition court decree dissolve fda oppose scheringploughs petition assurance particular date consent decree lift regulatory inspection scheringplough subject pharmacovigilance reporting requirement country jurisdiction include eu eumember states requirement differ jurisdiction jurisdiction include requirement report adverse event occur patient particular drug order alert drug manufacturer governmental agency potential problem table content pharmacovigilance inspection official british french medicine agency conduct request european medicine agency emea cite deficiency report process scheringplough continue work longterm action plan rectify deficiency provide regular update emea fourth quarter local uk emea regulatory authority conduct follow inspection assess scheringplough implementation action plan quarter authority inspect usbased component scheringplough pharmacovigilance system inspector acknowledge progress continue note significant concern quality system support scheringploughs pharmacovigilance process similarly follow inspection scheringploughs clinical trial practice uk inspector identify issue respect scheringploughs management clinical trial relate pharmacovigilance practice scheringplough intend continue upgrade skill process system clinical practice pharmacovigilance scheringplough remain committed accomplish work invest significant resource area february scheringplough begin global clinical harmonization program building clinical excellence trial design execution tracking strengthen scheringploughs scientific compliance rigor global basis scheringplough know action emea national authority response inspection possible action include inspection demand improvement report system criminal sanction scheringplough andor responsible individual change condition marketing authorization scheringplough product regulatory compliance postmarkete surveillance scheringplough engage clinical trial research country world clinical trial research activity comply stringent regulatory standard subject inspection eu local country regulatory authority failure comply current good clinical practice applicable law regulation quality process result delay approval clinical trial suspension ongoing clinical trial delay approval marketing authorization criminal sanction scheringplough andor responsible individual change condition marketing authorization scheringplough product increase cost clinical trial postmarkete surveillance certain market drug competitor industry raise safety concern lead recall withdrawal adverse labeling market product addition situation raise concern prescriber patient relate safety efficacy pharmaceutical product general scheringplough personnel regular open dialogue fda regulator review product label material regular basis new information know follow wake recent product withdrawal company significant safety issue health authority fda emea pmda japan continue increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication rereviewe select product market add uncertainty regulatory process great regulatory scrutiny especially advertising promotion particular directtoconsumer advertising similarly major health authority include fda emea pmda increase collaboration especially regard evaluation safety benefitrisk information medium attention increase current environment health authority regulatory action market safety labeling change regulatory prescribing marketing implication market extent previously see health authority pmda publicly acknowledge significant backlog workload resource constraint agency backlog cause long regulatory review time new indication product include initial approval zetia japan add uncertainty table content predict approval timeline market pmda committed correct backlog progress year expect continue foreseeable future uncertainty inherent government regulatory approval process include thing delays approval new product formulation indication affect scheringplough operation effect regulatory approval process operation predict scheringplough achieve significant number important regulatory approval include approval vytorin clarinex clarinex reditab clarinex new indication temodar nasonex significant approval include asmanex dpi dry powder inhalation noxafil eu australia pegintron japan new indication remicade scheringplough number significant regulatory submission file major market await approval pricing pressure describe specifically note legal environmental regulatory matter item financial statement supplementary datum pricing sale marketing program arrangement relate business practice scheringplough participant health care industry increase scrutiny federal state regulatory investigative prosecutorial administrative entity entity include department justice attorney office office inspector general department health human service fda federal trade commission ftc state attorney general office health care law certain governmental entity operate include federal state antikickback statute statutory common law false claim law construe broadly court permit government entity exercise significant discretion event governmental entity believe wrongdoing occur institute civil criminal proceeding institute resolve unfavorably subject scheringplough substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program scheringplough predict investigation affect marketing practice sale result material adverse impact scheringplough result operation cash flow financial condition business scheringploughs pharmaceutical product subject increasingly competitive pricing manage care group institution government agency group seek price discount market scheringplough pharmaceutical manufacturer require provide statutorily define rebate government agency order participate medicaid veterans health care program governmentfunde program international market scheringplough operates environment government mandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug enact acrosstheboard price cut method control cost scheringplough unable predict final form time future domestic international governmental health care initiative include passage law permit importation pharmaceutical effect operation cash flow reasonably estimate similarly effect operation cash flow decision government entity manage care group group concern formulary pharmaceutical reimbursement policy reasonably estimate medicare scheringplough predict net effect medicare prescription drug benefit market sale new medicare drug benefit medicare take effect january offer voluntary prescription drug coverage subsidize medicare million medicare beneficiary compete private prescription drug plan pdps medicare advantage plan scheringplough lead drug cover medicare b eg temodar integrilin intron table content medicare b provide payment physician service include prescription drug administer physician service manner drug reimburse medicare b limit scheringploughs ability offer large price concession large price increase drug scheringplough drug relatively small portion sale medicare population eg clarinex hepatitis c franchise scheringplough experience expand utilization vytorin zetia new drug schere plough rd pipeline great consequence scheringplough legislation impact pricing rebate discount competition market pharmaceutical product competitive scheringplough operation affect technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor new information clinical trial market product postmarkete surveillance generic competition scheringplough product mature addition patent position increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product effect operation competitive factor patent dispute predict outlook scheringplough track action build longterm high performance build base phase action agenda scheringplough continue investment support geographical expansion strategy plan sound promotional investment continue drive growth key brand worldwide scheringplough remains focus control overhead spending maintain rightsize sale force current opportunity scheringplough currently provide numeric guidance follow outlook helpful reader assess future prospect currently cholesterol lower market adjust entry market multiple generic form compete cholesterol product despite introduction new innovative compete treatment generic version compete product scheringplough continue anticipate sale vytorin zetia grow decision government entity manage care group group concern formulary reimbursement policy negatively impact dollar size andor growth cholesterol management market include vytorin zetia scheringploughs pipeline continue progress expect number patient scheringplough clinical trial increase substantially scheringplough continue invest research development focus enhance infrastructure upgrading process system talent result scheringplough expect rd expense exclude upfront payment grow fast adjust net sale adjust net sale define net sale plus assume percent global cholesterol joint venture net sale scheringplough believe growth comparison provide useful guideline review outlook rd expense result scheringplough action streamline manufacturing operation scheringplough expect annualize cost saving approximately million gross margin improve accordingly risk describe item risk factor cause actual result differ expectation provide section impact recently issue accounting standard september fasb issue sfas fair value measurement effective calendaryear company january statement define fair value establishe framework measure fair value accordance generally accept accounting principle expand disclosure fair value measurement statement codifie definition fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date table content standard clarifie principle fair value base assumption market participant use price asset liability establish fair value hierarchy prioritize information develop assumption scheringplough currently assess potential impact implement standard september sec staff issue staff accounting bulletin sab topic n sab financial statement consider effect prior year misstatement quantify misstatement current year financial statement effective calendaryear company december sab provide guidance prior year misstatement take consideration quantify misstatement current year financial statement purpose determine financial statement materially misstate guidance company account effect misstatement current year balance sheet impact current year income statement assess materiality current year misstatement current year misstatement quantify guidance sab topic financial statement materiality sab apply determine misstatement material implementation sab impact scheringplough financial statement july fasb issue fasb interpretation fin accounting uncertainty income taxis fin prescribe detail guidance financial statement recognition measurement disclosure uncertain tax position recognize enterprise financial statement accordance fasb statement accounting income taxis scheringplough require apply provision interpretation begin january provision fin apply exist uncertain income tax position effective date implementation fin cumulative effect apply provision interpretation report adjustment opening balance retain earning scheringplough evaluate potential impact fin adoption fin expect decrease opening retain earning january million million corresponding increase accrue liability account adoption interpretation critical accounting policy estimate follow accounting policy estimate consider significant change certain judgment assumption inherent policy affect scheringplough financial statement revenue recognition rebate discount return provision income taxis impairment intangible asset property accounting pension postretirement benefit plan account legal regulatory matter revenue recognition scheringploughs pharmaceutical product sell direct purchaser include wholesaler retailer certain health maintenance organization price discount rebate sale pay federal state agency indirect purchaser market participant manage care organization indemnify beneficiary health plan pharmaceutical cost pharmacy benefit manager scheringplough recognize revenue title risk loss pass purchaser reliable estimate follow determined commercial discount rebate arrangements ii rebate obligation certain federal state governmental program iii sale return normal course business table content recognize revenue scheringplough estimate record applicable commercial governmental discount rebate sale return expect grant product sell period amount deduct sale period reliable estimate item scheringplough defer recognition revenue estimate record prior period reevaluate process revenue recognition new product base specific fact circumstance include estimate acceptance rate establish product similar marketing characteristic absent ability reliable estimate rebate discount return scheringplough defer revenue recognition product discount grant base term arrangement wholesaler managedcare organization government purchaser certain market condition rebate estimate base sale contract term historical experience trend analysis project market condition market serve scheringplough evaluate market condition product group product primarily analysis thirdparty demand market research datum internally generate information datum information provide purchaser obtain party subject inherent limitation accuracy validity sale return estimate record base historical sale return information analysis recent wholesale purchase information consideration stocking level wholesaler forecast demand amount product exhibit unusual sale return pattern dating competition include expect generic introduction marketing matter specifically investigate analyze formulation return reserve scheringplough agreement major pharmaceutical wholesaler address number commercial issue product return time payment processing chargeback quantity inventory hold wholesaler respect quantity inventory hold wholesaler agreement provide financial disincentive wholesaler acquire quantity product excess necessary meet current patient demand use agreement scheringplough expect avoid situation scheringplough shipment product reflective current demand rebate discount return scheringploughs rebate accrual federal state governmental program include medicaid medicare december million million respectively commercial discount return rebate accrual december million million respectively accrual establish period relate revenue recognize result reduction sale establishment liability include total current liability case return receivable adjustment allowance provide account receivable case governmental rebate programs scheringploughs payment involve interpretation relevant statute regulation interpretation subject challenge change interpretive guidance governmental authority result challenge change affect estimate governmental rebate amount ultimately sufficient satisfy scheringplough obligation additional information governmental inquiry focus calculation rebate contain note legal environmental regulatory matter item financial statement supplementary datum addition possible result governmental challenge change interpretive guidance actual rebate materially exceed amount accrue table content follow summarize activity account relate accrued rebate sale return discount year end year end december december dollar millions accrue rebatesreturnsdiscount begin period provision rebate adjustment prioryear estimate payment provision return adjustment prioryear estimate return provision discount adjustment prioryear estimate discount grant accrue rebatesreturnsdiscount end period year end december adjustment prioryear estimate rebate include million result reversal accrue rebate amount record tricare retail pharmacy program august federal court appeal rule pharmaceutical manufacturer obligate pay formulate recording accrual management utilize assumption estimate include historical experience wholesaler datum projection market condition estimate lag time sale payment rebate utilization estimate forecast product demand amount discuss critical accounting policy entitle revenue recognition review accrual management perform sensitivity analysis consider differ assumption subject judgment rebate accrual calculation base scheringplough sensitivity analysis reasonably possible change assumption relate rebate accrual federal state governmental program favorably unfavorably impact net sale income taxis approximately million provision income taxis december taxis provide approximately billion earning international subsidiary scheringplough consider earning indefinitely reinveste international subsidiary scheringplough believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority scheringplough accrue liability identify tax contingency result tax position take challenge tax authority scheringplough tax reserve reflect scheringplough good estimate probable tax liability reasonably possible ultimate resolution tax matter materially great accrue scheringplough adopt fin accounting uncertainty income taxis january impact recently issue accounting standard discuss additional table content information expect impact scheringplough financial statement implementation fin scheringploughs potential tax exposure result vary application statute regulation interpretation include exposure intercompany term cross border arrangement utilization cash hold foreign subsidiary investment property scheringploughs cross border arrangement affiliate base internationally accept standard tax authority jurisdiction disagree subsequently challenge profit tax country scheringplough record valuation allowance reduce defer tax asset likely realize scheringplough consider ongoing prudent feasible tax planning strategy assess need valuation allowance event scheringplough determine able realize additional portion net defer tax asset adjustment valuation allowance increase income period determination likewise scheringplough subsequently determine able realize additional portion remain net defer tax asset future adjustment defer tax asset charge income period determination impairment intangible asset property intangible asset represent capitalize cost purchase goodwill patent license form intellectual property total million december annual amortization expense year estimate approximately million year base intangible asset record december value asset subject continue scientific medical marketplace uncertainty example market pharmaceutical product withdraw market safety reason marketing product occur pronounce warning amount capitalize product need reduce impairment event give rise impairment inherent risk pharmaceutical industry predict management regularly review intangible asset possible impairment certain scheringplough manufacturing site operate capacity overall cost operate manufacturing site significantly increase consent decree compliance activity scheringplough manufacturing cost base relatively fix action management significantly reduce scheringploughs manufacturing infrastructure involve complex issue result shift product manufacturing plant year construction regulatory requirement include revalidation registration requirement management continue review carry value certain manufacturing asset indication impairment future event decision lead additional asset impairment andor relate cost account pension postretirement benefit plan pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption scheringplough assess pension post retirement benefit plan assumption regular basis evaluate assumption scheringplough consider factor include evaluation discount rate expect rate return plan asset healthcare cost trend rate retirement age assumption scheringplough historical assumption compare actual result analysis current market condition asset allocation note retirement plan postretirement benefit item financial statement supplementary datum additional information discount rate pension postretirement benefit plan calculation evaluate annually modify reflect prevail market rate measurement date highquality fix income debt instrument portfolio provide future cash flow need pay benefit include benefit obligation come country debt instrument thinly trade estimate base available market rate table content actuarial assumption base management good estimate judgment assumption hold constant increase basis point discount rate estimate favorable impact million net pension postretirement benefit cost increase basis point expect rate return assumption estimate favorable impact million net pension postretirement benefit cost assumption hold constant decrease basis point discount rate estimate unfavorable impact million net pension postretirement benefit cost decrease basis point expect rate return assumption estimate unfavorable impact million net pension postretirement benefit cost expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return scheringplough determine expect return major asset class principally equities fix income real estate return expectation asset class base assumption economic growth inflation support longterm historical datum scheringplough actual experience return plan asset expect portfolio performance reflect contribution active management appropriate unrecognized net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption expect return base primarily calculate marketrelated value asset methodology asset gainslosse result actual return differ scheringplough expect return majority asset realize marketrelated value asset ratably fiveyear period total unrecognized net loss amount excess certain threshold amortize net pension postretirement benefit cost average remain service life employee target investment portfolio scheringplough pension plan allocate percent equity percent fix income investment percent real estate target investment portfolio scheringplough postretirement benefit plan allocate percent equity percent fix income investment portfolio equity weighting consistent longterm nature plan benefit obligation nonus pension plan target investment portfolio varies base duration pension liability local governmental rule regulation substantially investment equities fix income value base quote public market value investment real estate value base periodic appraisal september fasb issue sfas employer account define benefit pension postretirement plan amendment fasb statement r effective december scheringplough account retirement postretirement benefit plan accordance sfas shareholder equity december reduce approximately percent adoption sfas note retirement plan postretirement benefit item financial statement supplemental datum additional information sfas allow extended adoption date yearend measurement date requirement allow statement currently majority scheringploughs retirement postretirement benefit plan asset liability measure december remain plan measurement date yearend scheringplough anticipate adopt yearend measurement date effective december scheringplough expect material impact financial statement adoption account legal regulatory matter management judgment estimate require account legal regulatory matter ongoing basis include insurance coverage scheringplough review status claim investigation legal proceeding ongoing basis time time scheringplough settle resolve matter term condition management believe good interest scheringplough resolution table content claim investigation legal proceeding individually aggregate material adverse effect scheringplough result operation cash flow financial condition market risk disclosure scheringplough expose market risk primarily change foreign currency exchange rate less extent interest rate equity price follow describe nature risk foreign currency exchange risk scheringplough subsidiary country sale outside account approximately percent global sale virtually sale denominate currency local country scheringplough report profit cash flow expose change exchange rate date management deem cost effective engage formulabase program hedge profit cash flow international operation derivative financial instrument scheringplough international subsidiary purchase significant quantity inventory payable dollar manage level inventory relate payable rate inventory turnover provide level protection adverse change exchange rate risk adverse exchange rate change mitigate fact scheringplough international operation widespread addition point time scheringplough international subsidiary hold financial asset liability denominate currency dollar financial asset liability consist primarily shortterm thirdparty intercompany receivables payable change exchange rate affect translate value financial asset liability gain loss arise translation affect net income occasion scheringplough derivative hedge specific foreign currency exposure derivative transaction material interest rate equity price risk financial asset expose change interest rate andor equity price primarily cash equivalent shortterm investment debt equity security hold nonqualified trust employee benefit asset total billion december cash equivalent shortterm investment percent decrease interest rate decrease interest income approximately million security hold nonqualified trust longterm nature liability trust asset fund scheringplough exposure market risk deem low financial obligation expose variability interest rate primarily shortterm borrowing scheringplough currently maintain investment portfolio shortterm investment instrument excess borrowing accordingly scheringplough mitigate exposure change interest rate relate financial obligation scheringplough longterm debt outstanding percent decrease interest rate increase fair value debt approximately million schere plough currently expect refund debt disclosure notice cautionary statement private security litigation reform act management discussion analysis financial condition result operation section report write report oral statement time time scheringplough contain forwardlooke statement mean private security litigation reform act forward table content look statement relate strictly historical current fact base current expectation forecast future event identify forward look statement use word anticipate believe estimate expect forecast project intend plan potential similar word term particular forward look statement include statement relate future action ability access capital market prospective product product approval time condition regulatory approval patent intellectual property protection future performance result current anticipate product sale effort research development program estimate rebate discount return expense program reduce expense cost saving reduction work force outcome contingency litigation investigation growth strategy financial result forwardlooke statement publication turn wrong guarantee scheringplough financial operational performance performance scheringplough stock scheringplough assume obligation update forwardlooke statement factor cause actual result differ materially scheringploughs forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know possible predict identify factor refer item risk factor report incorporate reference identification important factor respect risk uncertainty item quantitative qualitative disclosure market risk market risk disclosure set forth item management discussion analysis table content item financial statement supplementary datum index financial statement statement consolidated operation year end december statement consolidated cash flow year end december consolidated balance sheet december statement consolidated shareholder equity year end december note consolidated financial statement report independent register public accounting firm table content scheringplough corporation subsidiary statement consolidated operation amount million share figure ear end ed de c e mber net sale cost sale sell general administrative research development incomeexpense net special charge equity income cholesterol joint venture incomeloss income taxis income tax expense net income cumulative effect change accounting principle cumulative effect change accounting principle net tax net incomeloss prefer stock dividend net incomeloss available common shareholder dilute earningsloss common share earning available common shareholder cumulative effect change accounting principle cumulative effect change accounting principle net tax dilute earningsloss common share basic earningsloss common share earning available common shareholder cumulative effect change accounting principle cumulative effect change accounting principle basic earningsloss common share dividend common share accompany note integral consolidated financial statement table content scheringplough corporation subsidiary statement consolidated cash flow amount million year e nded de ce mber operating activity net incomeloss cumulative effect change accounting principle net tax net income cumulative effect change accounting principle net tax adjustment reconcile net incomeloss net cash provide byused operating activity payment tax authority tax refund loss carryback special charge depreciation amortization accrue sharebase compensation change asset liability account receivable inventory prepaid expense asset account payable liability income taxis payable net cash provide operating activity invest activity capital expenditure disposition property equipment proceed transfer license purchase investment maturity investment net net cash investing activity financing activity cash dividend pay common shareholder cash dividend pay prefer shareholder proceed prefer stock issuance net shortterm borrowing payment shortterm borrowing reduction longterm debt stock option exercise net net cash provide financing activity effect exchange rate cash cash equivalent net decrease increase cash cash equivalent cash cash equivalent begin year cash cash equivalent end year supplemental disclosure cash pay interest net amount capitalize cash pay refunded income taxis note accompany note integral consolidated financial statement table content scheringplough corporation subsidiary consolidate balance sheet amount million share figure ec ember assets current asset cash cash equivalent shortterm investment account receivable allowance inventory defer income taxis prepaid expense current asset total current asset property cost land building improvement equipment construction progress total accumulate depreciation property net goodwill intangible asset net asset total asset liability shareholder equity current liability account payable shortterm borrowing current portion longterm debt foreign state income taxis accrue compensation accrue liability total current liability longterm liability longterm debt defer income taxis longterm liability total longterm liability commitment contingent liability note shareholder equity mandatory convertible preferred share par value issue share face value common share authorize share par value issue paidin capital retain earning accumulate comprehensive loss total treasury share cost total shareholder equity total liability shareholder equity accompany note integral consolidated financial statement table content scheringplough corporation subsidiary statement consolidated shareholder equity amount million ccumulate mandatory total convertible compre share prefer common paidin retain treasury hensive holder share share capital earning share loss equity balance january comprehensive incomeloss net loss foreign currency translation minimum pension liability net tax accordance sfas unrealize gain investment available sale net tax total comprehensive loss issuance preferred stock cash dividend common share dividend preferred share stock incentive plan balance december comprehensive incomeloss net income foreign currency translation minimum pension liability net tax accordance sfas total comprehensive income cash dividend common share dividend preferred share stock incentive plan balance december comprehensive income net income foreign currency translation minimum pension liability net tax accordance sfas unrealize gain investment available sale net tax total comprehensive income cash dividend pay common share dividend preferred share accrue dividend common share adjustment pension otherpostretirement liability adoption sfas net tax stock incentive plan balance december accompany note int egra l p art c olidated f cial st em e nt table content scheringplough corporation subsidiary note consolidated financial statement summary significant accounting policy overview scheringplough discover develop manufacture market medical therapy treatment enhance human health scheringplough market lead consumer brand overthecounter otc foot care sun care market operate global animal health business principle consolidation consolidated financial statement include scheringplough corporation subsidiary scheringplough intercompany balance transaction eliminate use estimate preparation financial statement conformity generally accept accounting principle require management estimate use assumption affect certain report amount disclosure actual amount differ equity method accounting scheringplough account share activity merckscheringplough cholesterol joint venture partnership joint venture merck co inc merck equity method accounting scheringplough significant influence joint venture operate financial policy accordingly scheringplough net sale include sale joint venture scheringplough share earning joint venture include consolidated net incomeloss equity income cholesterol joint venture include profit prescription pharmaceutical segment revenue sale vytorin zetia recognize joint venture title risk loss pass customer equity income joint venture exclude profit arise transaction scheringplough joint venture time underlying profit realize joint venture transaction party scheringplough merck note equity income cholesterol joint venture information joint venture cash cash equivalent cash cash equivalent include operate cash highly liquid investment original maturity month shortterm investment shortterm investment carry fair value classify availableforsale investment consist time deposit certificate deposit commercial paper maturity year inventory inventory value low cost market cost determine lastin firstout lifo method substantial portion inventory locate cost inventory determine firstin firstout method fifo depreciation property equipment depreciation provide estimate useful life property generally use straightline method table content note consolidated financial statement continue useful life property generally follow asset category ear building build improvement equipment scheringplough review carry value property equipment indication impairment accordance statement financial accounting standard sfas accounting impairment disposal longlive asset depreciation expense include accelerate depreciation relate manufacturing streamline million million million million respectively foreign currency translation net asset scheringplough international subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation account include comprehensive income loss remain international subsidiary nonmonetary asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include income exchange gain loss arise translate intercompany balance longterm investment nature record foreign currency translation account transactional exchange gain loss include income revenue recognition scheringploughs pharmaceutical product sell direct purchaser include wholesaler retailer certain health maintenance organization price discount rebate sale pay federal state agency indirect purchaser market participant manage care organization indemnify beneficiary health plan pharmaceutical cost pharmacy benefit manager scheringplough recognize revenue title risk loss pass purchaser reliable estimate follow determined commercial discount rebate arrangements ii rebate obligation certain federal state governmental program iii sale return normal course business recognize revenue scheringplough estimate record applicable commercial governmental discount rebate sale return expect grant product sell period amount deduct sale period reliable estimate item scheringplough defer recognition revenue estimate record prior period reevaluate process earning common share dilute earningsloss common share compute divide net incomeloss available common shareholder sum weight average number common share outstanding plus dilutive effect share issuable defer stock unit exercise stock option dilutive effect share issuable conversion schering plough mandatory convertible preferred stock table content note consolidated financial statement continue basic earningsloss common share compute divide net incomeloss available common shareholder weight average number common share outstanding goodwill intangible asset sfas goodwill intangible asset require intangible asset acquire individually group asset initially recognize measure base fair value intangible finite life amortize useful life intangible indefinite life include goodwill amortize scheringplough evaluate goodwill impairment fairvaluebased test goodwill determine impaired write estimate fair value scheringploughs goodwill primarily related animal health business asset include asset capitalize software million million december respectively amortization expense million million million respectively income taxis defer income taxis recognize future tax effect temporary difference financial income tax reporting basis scheringplough asset liability base enact tax law rate accounting sharebase compensation prior january scheringplough account stockbase compensation arrangement intrinsic value method sharebase employee compensation cost reflect net incomeloss scheringploughs defer stock unit performance plan stock option grant plan exercise price equal market value underlie common stock date grant effective january scheringplough account sharebase compensation accordance fasb statement financial accounting standard revise share base payment sfas r note sharebase compensation additional information impact recently issue accounting pronouncement september fasb issue sfas fair value measurement effective calendar year company january statement define fair value establishe framework measure fair value accordance generally accept accounting principle expand disclosure fair value measurement statement codifie definition fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date standard clarifie principle fair value base assumption market participant use price asset liability establish fair value hierarchy prioritize information develop assumption scheringplough currently assess potential impact implement standard september sec staff issue staff accounting bulletin sab topic n sab financial statement consider effect prior year misstatement quantify misstatement current year financial statement effective calendar year company december sab provide guidance prior year misstatement take consideration quantify misstatement current year financial statement purpose determine financial statement materially misstate guidance company account effect misstatement current year balance sheet impact current year income statement assess materiality current year misstatement current year misstatement quantify guidance table content note consolidated financial statement continue sab topic financial statement materiality sab apply determine misstatement material implementation sab impact scheringplough financial statement july fasb issue fasb interpretation fin accounting uncertainty income taxis fin prescribe detail guidance financial statement recognition measurement disclosure uncertain tax position recognize enterprise financial statement accordance fasb statement accounting income taxis scheringplough require apply provision interpretation begin january provision fin apply exist uncertain income tax position effective date implementation fin cumulative effect apply provision interpretation report adjustment opening balance retain earning note income taxis additional information expect impact adoption fin scheringploughs financial statement special charge manufacturing streamlining manufacturing streamline scheringplough implement change manufacture operation puerto rico new jersey streamline global supply chain enhance scheringplough longterm competitiveness change result phaseout closure scheringplough manufacturing operation manati puerto rico additional workforce reduction las piedras puerto rico new jersey total action result elimination position special charge special charge relate change scheringploughs manufacturing operation total million charge consist approximately million severance million fix asset impairment cost sale include cost sale approximately million consist million accelerate depreciation million inventory writeoff million charge relate closure scheringplough manufacturing facility manati puerto rico follow table summarize activity reflect consolidated financial statement relate change scheringploughs manufacturing operation complete charge include special total cash noncash accrue cost sale charge charge payment charge liability dollar millions accrue liability january severance asset impairment accelerate depreciation inventory writeoff total accrue liability december table content note consolidated financial statement continue accrue liability balance december expect pay quarter scheringplough expect incur material additional charge relate manufacturing streamlining action announce special charge activity special charge incur follow dollar million litigation charge employee termination cost asset impairment relate charge litigation charge litigation reserve increase million result total reserve approximately million massachusetts investigation investigation state litigation disclose awp litigation investigation note legal environmental regulatory matter august scheringplough announce reach agreement attorney office district massachusetts department justice settle massachusetts investigation aggregate million plus interest settlement relate massachusetts investigation awp investigation litigation ongoing remain reserve adequate cover matter subsequent december scheringplough payment total million relate massachusetts settlement include interest million scheringplough expect pay remain payment quarter note legal environmental regulatory matter additional information employee termination cost august scheringplough announce global workforce reduction initiative phase initiative voluntary early retirement program verp program eligible employee december elect early retirement receive enhance retirement benefit approximately employee elect retire program retire december total cost program approximately million comprise increase pension cost million increase postretirement health care cost million vacation payment million cost relate accelerate vest stock grant million amount recognize program million million respectively employee termination cost associate verp total million million respectively table content note consolidated financial statement continue follow summarize activity account related employee termination cost employee termination cost dollar million special charge liability balance december special charge incur credit retirement benefit plan liability disbursement special charge liability balance december special charge incur credit retirement benefit plan liability disbursement special charge liability balance december disbursement special charge liability balance december asset impairment charge year end december scheringplough recognize asset impairment charge million relate primarily consolidation scheringplough biotechnology organization year end december scheringplough recognize asset impairment charge million base discount cash flow charge million relate primarily shutdown small european research development facility equity income cholesterol joint venture scheringplough merck co inc merck enter separate set agreement jointly develop market certain product include cholesterollowere drug allergyasthma drug december cholesterol agreement expand include country world japan general company agree collaborative activity agreement operate virtual joint venture maximum degree possible rely respective infrastructure company agreement generally provide equal sharing development cost copromotion approve product company cholesterol agreement provide scheringplough merck jointly develop ezetimibe market zetia asia ezetrol europe oncedaily monotherapy ii coadministration statin drug iii oncedaily fixedcombination tablet ezetimibe simvastatin zocor merck cholesterolmodifye medicine combination medication ezetimibesimvastatin market vytorin inegy international country zetiaezetrol ezetimibe vytorininegy combination ezetimibesimvastatin approve use launch international market scheringplough utilize equity method accounting recording share activity merckscheringplough cholesterol joint venture scheringplough net sale include sale joint table content note consolidated financial statement continue venture cholesterol joint venture agreement provide share operating income generate joint venture base percentage vary product sale level country market scheringplough receive great share profit million annual zetia sale million annual zetia sale merck scheringplough partner generally share profit equally scheringplough allocation joint venture income increase milestone recognize partner share joint venture income operation subject reduction partner fail perform specify minimum number physician detail particular country partner agree annually minimum number physician detail country partner bear cost general sale force commercial overhead marketing joint venture product world canada puerto rico cholesterol agreement provide reimbursement partner physician detail set annual basis italy contractual include profit sharing calculation reimburse canada puerto rico equal partner physician detail multiply contractual fix fee scheringplough report amount equity income cholesterol joint venture amount represent reimbursement specific incremental identifiable cost scheringplough detail cholesterol product market addition amount reflective scheringplough sale effort relate joint venture scheringplough sale force relate cost associate joint venture generally estimate high year end december scheringplough recognize milestone million milestone relate certain european approval vytorin ezetimibesimvastatin scheringplough recognize milestone million relate approval ezetimibesimvastatin mexico certain condition specify joint venture agreement merck scheringplough earn additional milestone total million cost joint venture partner contractually share portion manufacturing cost specifically identify promotion cost include directtoconsumer advertising direct identifiable outofpocket promotion agree cost specific service market support market research market expansion specialty sale force physician education program certain specify research development expense generally share equally partner follow information provide summary component scheringploughs equity income cholesterol joint venture year end december dollar millions scheringploughs share net income include milestone respectively contractual amount physician detail elimination intercompany profit net total equity income cholesterol joint venture equity income joint venture exclude profit arise transaction scheringplough joint venture time underlying profit realize joint venture transaction party scheringplough merck virtual nature cholesterol joint venture scheringplough incur substantial cost sell general administrative cost reflect equity income bear overall cost structure scheringplough cost report respective line item statement consolidated operation separately identifiable cholesterol agreement provide table content note consolidated financial statement continue jointly own facility product result joint venture manufacture facility own scheringplough merck allergyasthma agreement provide joint development marketing partner oncedaily fixedcombination tablet contain claritin singulair singulair merck oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis january merckscheringplough respiratory joint venture report result phase iii clinical trial fixedcombination tablet contain claritin singulair phase iii study demonstrate sufficient add benefit treatment seasonal allergic rhinitis claritin singulair combination tablet approval country phase iii clinical development ongoing sharebased compensation prior january scheringplough account stock compensation arrangement intrinsic value method follow recognition measurement principle apb opinion accounting stock issue employee relate interpretation prior stockbase employee compensation cost reflect net income stock option scheringplough plan stock option grant require exercise price equal market value underlie common stock grant date scheringplough adopt statement financial accounting standard revise sharebased payment sfas r effective january sfas r require company recognize compensation expense equal fair value sharebase payment grant employee scheringplough elect modify prospective transition method adjustment prior period require result adopt sfas r method provision sfas r apply award grant date adoption unrecognized expense awards unveste date adoption base grant date fair value sfas r amend sfas statement cash flow require excess tax benefit reflect operate cash flow reflect finance cash flow november financial accounting standard board fasb issue fasb staff position fas r transition election relate accounting tax effect share base payment award scheringplough elect adopt transition method provide fasb staff position purpose calculate pool excess tax benefit available absorb tax deficiency recognize subsequent adoption sfas r second quarter stock incentive plan plan approve scheringplough shareholder term plan million schering plough authorize common share grant stock option award deferred stock unit officer certain employee scheringplough december december million option defer stock unit remain available future year grant plan scheringplough intends utilize unissued authorized share satisfy stock option exercise issuance defer stock unit grant issue retirementeligible employee prior adoption sfas r scheringplough recognize compensation cost state vest period stock option defer stock unit acceleration unrecognize compensation cost retirement employee adoption sfas r scheringplough recognize compensation cost sharebase grant january service period early employee retirement eligibility date service period award table content note consolidated financial statement continue implementation sfas r quarter scheringplough recognize benefit income million cumulative effect change accounting principle relate longterm compensation plan require account liability plan sfas r tax benefit recognize related stockbased compensation relate cash flow impact material scheringplough net operating loss position stock option stock option grant employee exercise price equal fair market value scheringplough stock date grant stock option plan generally vest year term seven year certain option grant previous plan vest long period range year term year compensation cost stock option recognize requisite service period separately vest portion stock option award expense recognize net estimate forfeiture vest period option accelerated method expense recognize approximately million weightedaverage assumption blackschole optionprice model follow dividend yield volatility riskfree interest rate expect term option year dividend yield base historical dividend yield expect volatility base historical volatility scheringplough common stock riskfree interest rate base treasury yield curve effect time grant period correspond expect life option expect term option represents weight average period time option grant expect outstanding give consideration vest schedule scheringploughs historical exercise pattern cash receive exercise stock option million million million respectively table content note consolidated financial statement continue stockbased compensation prior january determine intrinsic value method follow table provide supplemental information stock base compensation compute sfas dollar million share figure net income available common shareholder report add expense include report net income defer stock unit deduct pro forma expense stock option defer stock unit charge net income available common shareholder accordance sfas pro forma net income available common shareholder fair value method dilute earning common share dilute earning common share report pro forma diluted earning common share fair value method basic earning common share basic earning common share report pro forma basic earning common share fair value method summarize information stock option outstanding exercisable december follow utstande exerc able weighted weight weight number average average number average remain exercise exercise exercise price range option term year price option price thousand thousand weightedaverage fair value stock option grant respectively intrinsic value stock option exercise million million million respectively total fair value option vest million million million respectively december total remain unrecognized compensation cost relate nonveste stock option amount million amortize weight average remain requisite service period year table content note consolidated financial statement continue follow table summarize stock option activity december change year end current prior plan w eighte number average exercise option price thousand outstanding january grant exercise cancel expire outstanding december exercisable december aggregate intrinsic value stock option outstanding december million aggregate intrinsic value stock option currently exercisable december million intrinsic value stock option calculate base exercise price underlie award quote price scheringplough common stock reporting date follow table summarize nonveste stock option activity december change year end current prior plan w eighte number average fair option value thousand nonveste january grant vested forfeited nonveste december defer stock unit fair value defer stock unit determine base number share grant quote price scheringplough common stock date grant defer stock unit generally vest end year provide employee remain service scheringplough expense recognize straightline basis vest period defer stock unit payable equivalent number common share expense recognize million million million respectively table content note consolidated financial statement continue summarize information defer stock unit outstanding december follow ou tstande weight number average weight defer stock remain average defer stock unit price range unit term year fair value thousand weightedaverage fair value defer stock unit grant respectively total fair value defer stock unit vest million million million respectively december total remain unrecognized compensation cost relate deferred stock unit amount million amortize weightedaverage remain requisite service period year follow table summarize defer stock unit activity december change year end current prior plan number nonveste weight defer stock average unit fair value thousand nonveste january grant vested forfeited nonveste december incentive plan scheringplough compensation plan classify liability plan sfas r ultimate cash payout plan base scheringploughs stock performance compare stock performance peer group adoption sfas r january scheringplough recognize cumulative income effect change accounting principle million order recognize liability plan fair value income expense amount relate liability plan base change fair value report date fair value plan estimate lattice valuation model expect volatility assumption assumption appropriate determine fair value recognize exclusive impact cumulative effect change accounting principle statement consolidated operation relate liability award expense million december total remain unrecognized compensation cost relate incentive plan amount million amortize weightedaverage remain requisite service period year vary reporting period base change fair value table content note consolidated financial statement continue incomeexpense net component incomeexpense net follow dollar million interest cost incur capitalize construction interest expense interest income foreign exchange loss net total incomeexpense net scheringplough participate healthcare refinancing program adopt local government fiscal authority major european market december schering plough transfer million trade account receivables own foreign subsidiary thirdparty financial institution recourse transfer trade account receivable qualified sale account receivable sfas accounting transfer service financial asset extinguishment liability year end december loss transfer trade account receivable immaterial include interest expense cash flow transaction include change account receivable operating activity income taxis component consolidate incomeloss income taxis year end december follow dollar millions united states foreign total incomeloss income taxis include cumulative effect change accounting principle income cholesterol joint venture include table base jurisdiction income earn table content note consolidated financial statement continue component income tax expense year end december follow f ederal st eat f oreign tal dollar million current defer total current defer total current defer total scheringplough repatriate approximately billion accordance plan repatriation provision ajca maximum foreign earning qualify effectively reduce tax rate percent fourth quarter scheringplough accrue federal tax liability approximately million state income tax liability approximately million intend repatriation scheringplough continue use repatriated fund qualified spending scheringplough tax provision year end december include federal income tax benefit approximately million result irs notice issue august provision notice result reduction previously accrue tax liability attributable american job creation act ajca repatriation reduce net operating loss nol carry forward subsequent year prior ajca scheringplough intent indefinitely reinvest unremitted earning international subsidiary amount repatriate ajca scheringplough maintain intent indefinitely reinvest earning international subsidiary scheringplough provide defer taxis approximately billion undistributed foreign earning december determine tax liability arise earning remit practicable liability depend number factor include earning distribute operation generate taxable profit loss change tax planning strategy trigger scheringploughs intent repatriate earning ajca management long able conclude likely realize benefit net defer tax asset include benefit relate operating loss general scheringplough establish valuation allowance net defer tax asset december continue maintain valuation allowance net defer tax asset december defer income taxis provide temporary difference financial reporting basis tax basis scheringplough asset liability scheringplough defer tax asset result principally record certain item currently deductible tax purpose net operating loss tax credit carryforward scheringplough defer tax liability principally result use accelerate depreciation tax purpose table content note consolidated financial statement continue component scheringploughs defer tax asset liability december follow dollar million defer tax asset net operating loss nol carryforward tax credit carryforward postretirement employee benefit inventory relate sale return reserve litigation accrual total defer tax asset defer tax liability depreciation inventory valuation total defer tax liability defer tax valuation allowance net defer tax asset change valuation allowance decrease defer tax asset record nol carryforward offset increase defer tax asset record expense currently nondeductible tax purpose decrease defer asset record nol carryforward primarily attributable reduction estimate impact irs examination scheringplough open tax year impact statement operation balance subsequently increase decrease follow resolution examination defer tax asset net operating loss tax credit carryforward principally relate nol research development rd tax credit foreign tax credit federal alternative minimum tax amt credit carryforward december scheringplough approximately billion nol income tax purpose available offset future taxable income nol operate loss adjust difference financial tax report nol expire vary amount unused december scheringplough approximately million rd tax credit carryforward expire million foreign tax credit carryforward expire million amt tax credit carryforward indefinite life nol carryforward materially reduce examination scheringplough income tax return irs scheringplough reduce defer tax asset relate valuation allowance record nol tax credit carryforward reflect estimate resolution examination table content note consolidated financial statement continue difference income taxis base statutory tax rate scheringploughs income tax expense year end december follow dollar million income tax expensebenefit statutory rate increasedecrease taxis result low rate jurisdiction net federal benefit tax repatriate foreign earning act net credit operating loss tax benefit record permanent difference provision valuation allowance net defer tax asset provision tax matter state income tax net income tax effective tax rate low tax rate jurisdiction net primarily attributable scheringplough manufacturing subsidiary puerto rico singapore ireland operate incentive tax grant begin expire overall income tax expense primarily relate foreign taxis include benefit relate operating loss net consolidated income tax paymentsrefund exclusive payment relate tax examination litigation discuss million million million respectively january internal revenue service irs complete examination scheringplough federal income tax return scheringplough cash payment quarter form tax deposit approximately million anticipation settlement tax examination prevent additional irs interest charge payment fully satisfied liability associate tax examination consistent previously record reserve irs process complete examination scheringplough federal income tax return scheringplough anticipate examination complete end finalization examination result adjustment scheringplough accrual tax contingency nol report scheringplough income tax return scheringplough federal income tax return remain subject examination scheringplough believe accrual tax contingency adequate open year base experience interpretation tax law judgment potential action tax authority scheringplough accrue liability identify tax contingency result tax position take challenge tax authority scheringplough tax reserve reflect probable outcome identify tax contingency reasonably possible ultimate resolution tax matter materially great accrue scheringplough adopt fin accounting uncertainty income taxis january impact recently issue accounting standard note summary significant accounting policy scheringplough evaluate potential impact fin expect decrease opening retain earning january million million corresponding increase appropriate tax liability account adoption interpretation scheringplough potential tax exposure result vary application statute regulation interpretation include exposure intercompany term cross border arrangement utilization cash hold foreign subsidiary investment property scheringploughs cross border arrangement table content note consolidated financial statement continue affiliate base internationally accept standard tax authority jurisdiction disagree subsequently challenge profit tax country october irs auditor assert interest rate swap scheringplough enter unrelated party recharacterize loan affiliate company result additional tax liability tax year september scheringplough payment irs million income tax million interest scheringplough file refund claim tax interest irs december follow irss denial scheringplough claim refund scheringplough file suit district court district new jersey refund tax interest refund litigation currently discovery phase scheringplough tax reserve adequate cover abovementione payment retirement plan postretirement benefit plan description scheringplough define benefit pension plan cover eligible employee certain foreign country plan benefit normal retirement primarily base participant average final earning year service social security income modify early retirement death disability benefit available plan benefit fully vest year service plan provide continue accrual credit service employee opt postpone retirement remain employed scheringplough reach normal retirement age nonus pension plan offer benefit competitive local market condition addition scheringplough provide postretirement medical life insurance benefit primarily eligible retiree dependent postretirement benefit plan effective december scheringplough account retirement plan postretirement benefit plan plan accordance sfas employer account define benefit pension postretirement plan amendment sfas r sfas require recognition asset overfunde plan liability underfunde plan scheringplough consolidated balance sheet statement require recognition change fund status plan year change occur provide sfas requirement measure plan asset liability fiscal yearend extend effective year end december currently majority scheringploughs retirement postretirement benefit plan asset liability measure december table content note consolidated financial statement continue incremental effect result implementation sfas individual line item scheringplough consolidated balance sheet december follow balance sheet balance sheet amount prior amount sfas sfas sfas sfas adjustment adjustment adjustment adjustment asset intangible asset longterm asset include defer tax asset liability accrue compensation longterm liabilities equity accumulate comprehensive loss net tax effect december include scheringploughs accumulate comprehensive loss million million net tax effect cost recognize component net periodic benefit cost pursuant sfas employer account pension sfas employer account postretirement benefit pension component cost december follow postretirement retirement plan benefit actuarial loss prior service costcredit total actuarial loss primarily represent cumulative difference actuarial assumption actual return plan asset change discount rate plan experience total loss amount net excess certain threshold amortize net pension postretirement benefit cost average remain service life employee amount accumulate comprehensive loss expect recognize component net periodic cost follow postretirement retirement plan benefit actuarial loss recognition prior service costcredit recognition table content note consolidated financial statement continue actuarial assumption consolidated weight average assumption determine benefit obligation december th er post retirement retirement plan benefit discount rate rate increase future compensation na na assumption develop benefit obligation yearend consolidated weight average assumption determine net benefit cost year end december ther retirement plan postretirement benefit discount rate longterm expect rate return plan asset rate increase future compensation na na na assumption determine net periodic benefit cost year establish end previous year assumption determine benefit obligation establish yearend net periodic benefit cost actuarial present value benefit obligation base actuarial assumption determine annually base evaluation longterm trend market condition impact cost provide retirement benefit longterm expect rate return plan asset derive return assumption determine major asset class equity fix income real estate proportional basis return expectation asset class base largely assumption economic growth inflation support longterm historical datum weight average assume healthcare cost trend rate postretirement measurement purpose percent trend percent percent increase assume healthcare cost trend rate increase combined postretirement service interest cost million postretirement benefit obligation million percent decrease assume health care cost trend rate decrease combined postretirement service interest cost million postretirement benefit obligation million average retirement age assume base annual rate retirement experience scheringplough component net periodic benefit cost net pension postretirement benefit cost total million million million respectively table content note consolidated financial statement continue component net pension postretirement benefit expense follow ther retirement plan postretirement benefit dollar million service cost interest cost expect return plan asset amortization net termination benefit settlement net pension postretirement benefit cost accordance fasb staff position accounting disclosure requirement relate medicare prescription drug improvement modernization act medicare act scheringplough begin accounting effect federal subsidy medicare act quarter result scheringplough net postretirement benefit expense reduce million reduction postretirement benefit expense consist reduction service cost interest cost net amortization million million million respectively benefit obligation component change benefit obligation follow p os tretire ment retirement plan benefit dollar million benefit obligation begin year service cost interest cost medicare drug subsidy receive participant contribution effect exchange rate change benefit pay acquisitionsplan transfer actuarial lossesgain include assumption change plan amendment termination benefit curtailment settlement benefit obligation end year benefit obligation overfunde plan benefit obligation underfunde plan table content note consolidated financial statement continue fund status balance sheet presentation component change plan asset follow th er post retirement retirement plan benefit dollar million fair value plan asset primarily stock bond begin year actual gain loss plan asset employer contribution participant contribution acquisitionsplan transfer effect exchange rate change settlement benefit pay fair value plan asset end year plan asset overfunde plan plan asset underfunde plan addition plan asset indicate december security investment million million respectively hold nonqualified trust designate provide pension benefit certain underfunde plan accordance sfas december net asset overfunde plan million relate scheringplough retirement plan include longterm asset net liability underfunde plan december total million follow retirement postretirement plan benefit dollar millions accrue compensation current longterm liability total prior december scheringplough account retirement plan postretirement benefit plan accordance sfas r follow table reconciliation fund status plan net assetliability december retirement postretirement plan benefit dollar million benefit obligation excess plan asset post measurement date contribution unrecognize prior service cost unrecognize net actuarial loss net assetliability end year table content note consolidated financial statement continue december component net assetliability record consolidated balance sheet follow retirement postretirement plan benefit dollar millions prepaid benefit cost accrue benefit cost intangible asset accumulate comprehensive loss net assetliability end year december scheringplough additional minimum pension liability million primarily relate domestic retirement plan result adjustment accumulate comprehensive loss net tax million december accumulate benefit obligation abo retirement plan million million respectively aggregate accumulate benefit obligation fair value plan asset retirement plan accumulate benefit obligation excess plan asset million million respectively december million million respectively december plan asset fair value asset allocation consolidated retirement plan december target allocation follow pe rce ntage f target plan asset allocation december asset category equity security debt security real estate total asset allocation postretirement benefit trust december target allocation follow pe rce ntage f target plan asset allocation december asset category equity security debt security total scheringplough investment relate plan broadly diversify consist primarily equity fix income security objective generate longterm investment return consistent acceptable level overall portfolio market value risk asset periodically rebalance target allocation table content note consolidated financial statement continue estimate future benefit payment follow benefit payment reflect expect future service appropriate expect pay retirement postretirement plan benefit dollar million year scheringplough practice fund qualified pension plan sufficient amount meet minimum requirement set forth applicable law scheringplough expect contribute approximately million retirement plan include approximately million retirement plan define contribution plan scheringplough make contribution define contribution saving plan equal percent eligible employee earning plus match percent eligible employee earning base employee contribution plan total scheringplough contribution plan million million respectively earning common share follow table reconcile component basic dilute earningsloss share computation dollar share million eps numerator net incomeloss cumulative effect change accounting principle prefer stock dividend add cumulative effect change accounting principle net tax preferred stock dividend net incomeloss available common shareholder eps denominator average share outstanding basic eps dilutive effect option defer stock unit average share outstanding diluted eps equivalent common share issuable scheringploughs stock incentive plan exclude computation dilute eps effect antidilutive million million million respectively year end december respectively addition year end december million million million common share respectively obtainable conversion mandatory convertible preferred stock exclude computation dilute earning share effect antidilutive table content note consolidated financial statement continue accumulate comprehensive loss component accumulate comprehensive incomeloss december follow dollar million foreign currency translation adjustment minimum pension liability net tax effect accordance sfas provision pension postretirement liability net tax effect accordance sfas provision unrealize gain investment available sale net tax total note retirement plan postretirement benefit additional information impact scheringplough financial statement adoption sfas effective december scheringplough account retirement postretirement benefit plan accordance sfas implementation sfas result increase million net tax effect accumulate comprehensive loss reduce shareholder equity gross unrealized pretax gain investment million million respectively unrealize loss immaterial inventory inventory consist follow december dollar million finish product good process raw material supply total inventory inventory classify noncurrent asset include noncurrent asset million inventory expect sell year inventory value lastin firstout lifo basis comprise approximately percent percent total inventory december respectively estimate replacement cost total inventory december million million respectively cost inventory determine firstin firstout method fifo table content note consolidated financial statement continue intangible asset component intangible asset net follow december gross gross carrying accumulate carry accumulate amortization net amortization net dollar million patent license trademark total intangible asset include pension asset million december effective december pension asset eliminate result scheringplough adoption sfas note retirement plan postretirement benefit plan additional information patent license trademark amortize straightline method respective useful life residual value intangible asset estimate zero fourth quarter scheringplough receive right trademark tradename entity minority interest trademark tradename fair value approximately million trademark tradename include scheringplough intangible asset december amortize straightline method year include intangible asset approximately million relate license copromotion agreement bayer amount amortize effective useful life agreement range seven year note product license acquisition additional information transaction amortization expense relate intangible asset million million million respectively include primarily sell general administrative expense statement consolidated operation intangible asset review determine recoverability compare carry value expect undiscounted future cash flow event circumstance warrant review annual amortization expense relate intangible asset year expect approximately million product license acquisition august scheringplough announce exercise right develop commercialize centocor inc centocor golimumab new antitnfalpha monoclonal antibody develop therapy treatment rheumatoid arthritis immunemediate inflammatory disease pursuant exercise scheringplough receive exclusive worldwide marketing right golimumab exclude japan china include hong kong taiwan indonesia exchange right agreement scheringplough upfront payment million centocor tax benefit million payment include research development expense year end december scheringplough sharing development cost centocor scheringplough centocor collaborate resolve difference party opinion expiration date scheringplough right golimumab august scheringplough receive determination arbitration right market golimumab extend year commercial sale territory centocor appeal rule effective september scheringplough restructure integrilin copromotion agreement millennium term restructure agreement scheringplough acquire exclusive development commercialization right integrilin exchange upfront payment million royalty integrilin sales scheringplough agree pay minimum royalty million year millennium table content note consolidated financial statement continue scheringplough purchase exist integrilin inventory millennium million upfront payment capitalize include intangible asset scheringplough enter collaboration license agreement toyama chemical co ltd toyama term agreement scheringplough acquire exclusive worldwide right exclude japan korea china develop use sell garenoxacin human veterinary use exclude topical ophthalmic application garenoxacin toyamas quinolone antibacterial agent currently regulatory review connection execution agreement scheringplough incur charge second quarter fee million toyama expense report research development year end december scheringplough enter strategic agreement bayer intend enhance scheringploughs pharmaceutical resource term agreement schere plough exclusive right puerto rico market sell distribute avelox cipro antibiotic use exclude certain topical formulation administration eye ear scheringplough pay bayer royalty generally excess percent product base sale agreement scheringplough undertake bayer commercialization activity erectile dysfunction medicine levitra bayer copromotion agreement glaxosmithkline plc japanese market bayer comarket scheringploughs cholesterolabsorption inhibitor zetia approve scheringplough receive record defer revenue million relate sale zetia copromotion right bayer defer revenue begin recognize regulatory approval japan zetia currently regulatory review japan certain circumstance zetia receive regulatorymarkete approval japan certain date require repay bayer agreement bayer potentially restrict scheringplough marketing product compete product agreement result schere plough expect sublicense right garenoxacin quinolone antibacterial agent scheringplough license toyama shortterm borrowing longterm debt commitment short longterm borrowing scheringplough outstanding borrowing december follow dollar millions shortterm commercial paper shortterm borrowing current portion longterm debt current portion capital lease total shortterm borrowing longterm year senior unsecured note year senior unsecured note capital lease total longterm borrowing scheringplough shortterm borrowing consist primarily bank loan commercial paper issue weight average interest rate shortterm borrowing percent percent december respectively table content note consolidated financial statement continue senior unsecured note november scheringplough issue billion aggregate principal percent senior unsecured note billion aggregate principal percent senior unsecured note net proceed offer billion interest note payable semiannually subject rate adjustment follow rating assign particular series note moodys investors service inc moodys standard poor rating service sp change rating set forth interest rate payable series note initial interest rate percent note percent note plus additional interest rate set forth moodys sp additional interest rate moodys rating sp rating baa bbb baa bbb baa bbb ba bb event interest rate note increase percent initial coupon rate percent percent respectively moodys sp subsequently upgrade rating interest rate correspondingly reduce percent percent respectively furthermore interest rate payable particular series note return percent percent respectively rate adjustment provision permanently cease apply follow downgrade moodys sp respectively note subsequently rate baa moodys bbb sp issuance note rate moodys sp july moodys lower rating note baa accordingly interest payable note increase basis point effective december result percent interest rate payable note percent interest rate payable note increase december note rate baa moodys sp senior unsecured note redeemable scheringplough option time redemption price equal great percent principal note sum present value remain schedule payment principal interest discount rate treasury note comparable remain term plus basis point note basis point note credit facility scheringplough billion credit facility mature require scheringplough maintain total debt capital ratio percent credit line available general corporate purpose consider support scheringplough commercial paper borrowing borrowing credit facility draw parent company whollyowne international subsidiary accompany parent guarantee facility require compensating balance nominal commitment fee pay december million draw facility whollyowne international subsidiary purpose funding repatriation ajca borrowing fully repay december borrowing outstanding facility addition credit facility scheringplough enter million credit facility fourth quarter purpose funding repatriation ajca december entire draw whollyowne international subsidiary fund repatriation facility pay terminate addition scheringplough international subsidiary approximately million available unused line credit financial institution december table content note consolidated financial statement continue commitment total rent expense amount million million million respectively future annual minimum rental commitment year non cancelable operating lease december follow million million million million million aggregate minimum lease obligation million december scheringplough commitment total million million relate capital expenditure respectively financial instrument sfas derivative instrument financial hedging activity amend require derivative record balance sheet fair value addition statement require effective portion qualify cash flow hedge recognize income hedge item affect income change fair value derivative qualify fair value hedge change fair value hedge risk recognize occur change fair value derivative qualify hedge treatment ineffective portion qualifying hedge recognize income occur risk policy objective scheringplough expose market risk primarily change foreign currency exchange rate less extent interest rate equity price change currently schere plough deem cost effective engage formulabase program hedge profit cash flow international operation derivative financial instrument limit basis scheringplough hedge selective foreign currency risk derivative scheringplough international subsidiary purchase significant quantity inventory payable dollar manage level inventory relate payable rate inventory turnover provide natural level protection adverse change exchange rate furthermore risk adverse exchange rate change somewhat mitigated fact scheringplough international operation widespread scheringplough mitigate credit risk derivative instrument deal counterpartie consider high credit quality accordingly scheringplough anticipate loss nonperformance scheringplough enter derivative instrument generate trading profit table present carry value estimate fair value certain scheringplough financial instrument december estimate fair value determine base market price available dealer quote carry value financial instrument include cash cash equivalent approximate estimate fair value december carry estimate carry estimate value fair value value fair value dollar million asset shortterm investment longterm investment liabilitie shortterm borrowing current portion longterm debt longterm debt table content note consolidated financial statement continue longterm investment longterm investment include noncurrent asset primarily consist debt equity security hold nonqualified trust fund longterm employee benefit obligation include liability consolidated balance sheet asset fund relate liability shareholder equity scheringplough authorize share prefer stock consist prefer share designate series junior participate prefer stock prefer share designate percent mandatory convertible preferred stock prefer share designation determine percent mandatory convertible prefer stock shelf registration august scheringplough issue share percent mandatory convertible preferred stock prefer stock face value billion net proceed scheringplough billion deducting commission discount underwriting expense share prefer stock automatically convert common share scheringplough depend average closing price scheringplough common share period immediately precede mandatory conversion date september define prospectus prefer shareholder elect convert time prior september minimum conversion ratio common share share prefer stock additionally time prior mandatory conversion date closing price scheringplough common share exceed trading day period consecutive trading day scheringplough elect cause conversion prefer stock outstanding minimum conversion ratio common share prefer share prefer stock accrue dividend annual rate percent share outstanding dividend cumulative date issuance extent scheringplough legally permit pay dividend board director declare dividend payable scheringplough pay dividend dividend payment date dividend payment date march june september december dividend pay december december scheringplough ability issue million principal security currently effective security exchange commission sec shelf registration treasury stock summary treasury share transaction year end december follow share millions share balance january stock incentive plan activity share balance december table content note consolidated financial statement continue include treasury share balance million share acquire subsidiary scheringplough openmarket purchase program share consider treasury share new jersey law like treasury share vote consider outstanding share determine necessary vote approve matter submit stockholder vote subsidiary receive dividend share prefer share purchase right scheringplough preferred share purchase right outstanding attach presently trade scheringplough common share exercisable right exercisable person group acquire percent scheringplough common stock announce tender offer complete result ownership person group percent scheringplough common stock person group acquire percent scheringplough outstanding common stock merger business combination transaction right entitle holder acquirer purchase common share scheringplough market value twice exercise price right exercise price right follow acquisition person group beneficial ownership percent percent scheringplough common stock board director exchange right right own acquirer exchange ratio common share twohundredth share series junior participate prefer stock right prior acquisition person group beneficial ownership percent scheringplough common stock right redeemable right option board director right expire july early redeem exchange board director authorize reduce percent threshold refer great sum percent large percentage outstanding share common stock know scheringplough beneficially own person group affiliate associate person ii percent follow acquisition person group beneficial ownership percent scheringplough common stock reduction adversely affect interest holder right insurance coverage scheringplough maintain insurance coverage deductible selfinsurance management believe adequate need current circumstance coverage reflect market condition include cost availability exist time write relationship insurance coverage selfinsurance vary accordingly result recent external event availability insurance restrictive scheringplough consider impact change continually assess good way provide insurance need future scheringplough selfinsure substantial proportion risk relate product liability table content note consolidated financial statement continue segment information scheringplough reportable segment prescription pharmaceutical consumer health care animal health segment sale profit datum follow consistent scheringplough current management reporting structure prescription pharmaceutical segment discover develop manufacture market human pharmaceutical product consumer health care segment develop manufacture market overthecounter foot care sun care product primarily animal health segment discover develop manufacture market animal health product net sale major product segment dollar million prescription pharmaceutical remicade nasonex pegintron clarinexaerius temodar claritin rx integrilin rebetol avelox introna caelyx subutex elocon cipro pharmaceutical consumer health care otc foot care sun care animal health consolidate net sale net sale geographic area dollar millions united states europe canada pacific area asia latin america total international consolidated net sale table content note consolidated financial statement continue scheringplough subsidiary country outside net sale present geographic area scheringplough customer locate follow foreign country account percent consolidated net sale past year consolidated consolidated consolidated net sale net sale net sale net sale net sale net sale dollar million total international net sale france japan canada italy net sale customer sale single customer account percent scheringploughs consolidate net sale past year follow consolidated consolidated consolidated net sale net sale net sale net sale net sale net sale dollar million mckesson corporation cardinal health profit segment e r end decem r dollar million prescription pharmaceutical consumer health care animal health corporate include net interest income million million respectively million net interest expense consolidate profitloss tax cumulative effect change accounting principle scheringplough net sale include sale vytorin zetia manage partnership merck scheringplough account joint venture equity method accounting note equity income cholesterol joint venture additional information profit prescription pharmaceutical segment include equity income cholesterol joint venture corporate include interest income expense foreign exchange gain loss headquarters expense special charge miscellaneous item accounting policy segment report describe note summary significant accounting policy corporate include special charge million primarily relate change scheringploughs manufacturing operation puerto rico announce june relate prescription pharmaceutical segment include cost sale charge approximately table content note consolidated financial statement continue million manufacturing streamlining action primarily relate prescription pharmaceutical segment corporate include special charge million include million employee termination cost million asset impairment charge increase litigation reserve million result total reserve million represent scheringplough current estimate resolve massachusetts investigation investigation state litigation disclose awp litigation investigation note legal environmental regulatory matter estimate charge relate reportable segment follow prescription pharmaceutical million consumer health care million animal health million corporate million corporate include special charge million include million employee termination cost million asset impairment charge million closure cost primarily related exit small european research development facility estimate charge relate reportable segment follow prescription pharmaceutical million consumer health care million animal health million corporate million supplemental sale information sale product comprise percent scheringplough international sale year end december follow mount p ercentage dollar million nasonex international remicade pegintron longlive assets geographic location dollar millions united states singapore ireland puerto rico total longlive asset show geographic location primarily property scheringplough disaggregate asset segment basis internal management report information present consent decree scheringplough agree fda entry consent decree resolve issue relate compliance current good manufacturing practice cgmp certain scheringploughs facilities new jersey puerto rico consent decree decree table content note consolidated financial statement continue summary decree require scheringplough payment total million equal installment million pay addition decree require scheringplough complete revalidation program manufacturing process produce bulk active pharmaceutical ingredient finish drug product cover facility implement comprehensive cgmp work plan facility decree require foregoing complete accordance strict schedule provide possible imposition additional payment event scheringplough adhere approve schedule final completion work subject certification independent expert certification turn subject fda acceptance september scheringplough complete revalidation party certification bulk active pharmaceutical ingredient december schere plough complete revalidation thirdparty certification finish drug product scheringplough complete significant step cgmp work plan december requirement complete accordance schedule require decree scheringplough obtain thirdparty certification completion work plan require decree possible fda disagree expert certification event possible fda assess additional payment permit decree describe detail general cgmp work plan contain significant step timely satisfactory completion subject payment thousand business day deadline miss payment exceed million million year payment subject overall cap million scheringplough expense additional payment assess decree incur term decree provide fda notify scheringplough significant violation fda law regulation decree fiveyear period decree entry scheringplough petition court decree dissolve fda oppose scheringploughs petition assurance particular date consent decree lift legal environmental regulatory matter background scheringplough involve claim investigation legal proceeding scheringplough record liability contingency probable liability incur reasonably estimate scheringplough adjust liability contingency reflect current good estimate probable loss minimum liability case well estimate determinable scheringplough record minimum probable range liability expect insurance recovery consider determine amount record liability environmental relate matter scheringplough believe loss contingency reasonably possible probable loss estimate liability record liability reasonably possible disclosure loss contingency scheringplough review status claim investigation legal proceeding ongoing basis include related insurance coverage time time scheringplough settle resolve matter term condition management believe good interest scheringplough resolution claim investigation legal proceeding individually aggregate material adverse effect scheringplough result operation cash flow financial condition addition resolution investigation involve injunctive administrative remedy adversely impact business exclusion government reimbursement program turn material adverse impact business future financial condition cash flow result operation table content note consolidated financial statement continue matter discuss remainder note record liability contingency december relate expense incur year end december material opinion management base advice legal counsel ultimate outcome matter matter discuss remainder note material impact scheringplough result operation cash flow financial condition patent matter describe patent trademark intellectual property right business intellectual property protection critical scheringplough ability successfully commercialize product innovation potential litigation scheringploughs intellectual property right exist initiate party attempt abridge scheringplough right scheringplough protect right patent matter describe potential material effect scheringplough dr scholl freeze away patent july orasure technology file action district court eastern district pennsylvania allege patent infringement scheringplough healthcare product sale dr scholl freeze away wart removal product complaint seek permanent injunction unspecified damage include treble damage massachusetts investigation august scheringplough announce reach agreement attorney office district massachusetts settle investigation involve schering plough sale marketing clinical trial practice program warrick pharmaceuticals warrick scheringploughs generic subsidiary massachusetts investigation investigation focus follow allege practice provide remuneration manage care organization physician induce purchase schering pharmaceutical product offlabel marketing drug submit false pharmaceutical pricing information government purpose calculate rebate require pay medicaid program agreement provide aggregate settlement million criminal fine million million resolve civil aspect investigation january schere sale corporation subsidiary scheringplough plead guilty count conspiracy false statement government connection settlement scheringplough sign addendum exist corporate integrity agreement office inspector general department health human service addendum affect schering plough ongoing business customer include federal government table content note consolidated financial statement continue scheringplough record liability million relate massachusetts investigation investigation state litigation describe awp litigation investigation settlement million relate massachusetts investigation awp litigation investigation ongoing awp litigation investigation scheringplough continues respond exist new litigation certain state private payor investigation department health human services department justice state industry scheringplough practice average wholesale price awp scheringplough cooperating investigation litigation investigation relate awp pharmaceutical company certain drug improperly exceed average price pay provider consequence result unlawful inflation certain reimbursement drug state program private payor base awp complaint allege violation federal state law include fraud medicaid fraud consumer protection violation claim majority case plaintiff seek class certification case class certify outcome litigation investigation include substantial damage imposition substantial fine penalty injunctive administrative remedy security class action litigation federal security litigation follow scheringploughs announcement fda conduct inspection scheringplough manufacture facility new jersey puerto rico issue report cite deficiency concern compliance current good manufacturing practice lawsuit file scheringplough certain name officer lawsuit allege defendant violate federal security law allegedly fail disclose material information make material misstatement specifically allege scheringplough fail disclose allege risk new drug application clarinex delay result manufacturing issue allege scheringplough fail disclose allege depth severity manufacturing issue complaint consolidate action district court district new jersey consolidated amend complaint file october purport represent class shareholder purchase share scheringplough stock february complaint seek compensatory damage behalf class court certify shareholder class october discovery ongoing shareholder derivative action lawsuit file district court district new jersey scheringplough certain officer director director seek damage behalf scheringplough include disgorgement trading profit defendant allegedly obtain basis material nonpublic information complaint allege failure disclose material information breach fiduciary duty director relate fda inspection investigation scheringplough pricing practice sale marketing clinical trial practice lawsuit shareholder derivative action purport assert claim behalf scheringplough shareholder derivative action pende district court district new jersey consolidate action august erisa litigation march scheringplough serve putative class action complaint file district court new jersey allege scheringplough retire chairman ceo president richard jay kogan scheringploughs employee saving plan plan administrator current director certain corporate officer messrs larosa moore breach fiduciary obligation certain participant table content note consolidated financial statement continue plan complaint seek damage loss allegedly suffer plan complaint dismiss june plaintiff appeal august court appeal circuit reverse dismissal district court matter remand district court proceeding kdur antitrust litigation scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle relate generic version kdur scheringploughs longacte potassium chloride product supplement cardiac patient lederle upsher smith file abbreviate new drug application follow commencement ftc administrative proceeding allege anticompetitive effect settlement allege class action suit file federal state court behalf direct indirect purchaser k dur scheringplough upshersmith lederle suit claim violation federal state antitrust law state statutory common law cause action suit seek unspecified damage discovery ongoing thirdparty payor action support class action litigation file follow announcement settlement massachusetts investigation plaintiff action seek damage behalf thirdparty payor result allegation offlabel promotion improper payment physician issue massachusetts investigation tax matter october irs auditor assert interest rate swap scheringplough enter unrelated party recharacterize loan affiliate company result additional tax liability tax year september scheringplough payment irs million income tax million interest scheringplough file refund claim tax interest irs december follow irss denial scheringplough claim refund scheringplough file suit district court district new jersey refund tax interest refund litigation currently discovery phase scheringplough tax reserve adequate cover mention payment pende administrative obligation connection settlement investigation department justice attorney office eastern district pennsylvania scheringplough enter fiveyear corporate integrity agreement cia cia amend august connection settlement massachusetts investigation commence new fiveyear term disclose note consent decree scheringplough subject obligation consent decree fda failure comply obligation cia consent decree result financial penalty matter nitrodur investigation august scheringplough receive civil investigative subpoena issue office inspector general department health human service seek document concern scheringplough classification nitrodur medicare rebate purposes scheringploughs use nominal pricing bundle product sale scheringplough cooperate investigation appear subpoena number address pharmaceutical company concern inquiry issue relate payment government rebate table content note consolidated financial statement continue french matter base complaint french competition authority competitor france pursuant court order french competition authority obtain document french subsidiary scheringplough relate product subsidiary market sell resolution matter adverse french subsidiary result imposition civil fine injunctive administrative remedy environmental scheringplough responsibility environmental cleanup state local federal law include comprehensive environmental response compensation liability act commonly know superfund superfund site equivalent site state law scheringplough allege potentially responsible party prp schering plough believe remote time material liability relation site scheringplough estimate obligation cleanup cost superfund site base information obtain federal environmental protection agency epa equivalent state agency andor study prepare independent engineer probable cost pay prps scheringplough record liability environmental assessment andor cleanup probable loss incur reasonably estimate table content report independent register public accounting firm board director shareholder scheringplough corporation audit accompany consolidated balance sheet scheringplough corporation subsidiary company december relate consolidated statement operation shareholder equity cash flow year period end december audits include financial statement schedule list index item financial statement financial statement schedule responsibility company management responsibility express opinion financial statement financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position scheringplough corporation subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion financial statement schedule consider relation basic consolidated financial statement take present fairly material respect information set forth discuss note consolidated financial statement effective january company adopt statement financial accounting standard sfas revise sharebased payment discuss note consolidated financial statement effective december company adopt sfas employer account define benefit pension postretirement plan audit accordance standard public company accounting oversight board united states effectiveness company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion management assessment effectiveness company internal control financial report unqualified opinion effectiveness company internal control financial reporting deloitte touche llp parsippany new jersey february table content scheringplough corporation subsidiary quarterly datum unaudite nth end march june september december dollar million share figure net sale cost sale gross margin sell general administrative research development incomeexpense net special charge equity income cholesterol joint venture income income taxis income tax expense net incomeloss cumulative effect change accounting principle cumulative effect change accounting principle net tax net incomeloss dividend prefer share net incomeloss available common shareholder dilute earningsloss common share earningloss available common shareholder cumulative effect change accounting principle cumulative effect change accounting principle net tax dilute earning common share basic earningsloss common share earningsloss available common shareholder cumulative effect change accounting principle cumulative effect change accounting principle net tax basic earningsloss common share dividend common share common share price high low average share outstanding diluted eps million average share outstanding basic eps million table content net sale quarter include favorable impact approximately million result reversal previously accrue rebate amount tricare retail pharmacy program federal court appeal rule pharmaceutical manufacturer obligate pay note special charge manufacture change consolidate financial statement additional information relate special charge charge schere plough announce manufacturing change scheringplough approximate number holder record common share january item change disagreement accountant account financial disclosure applicable item control procedure management include chief executive officer chief financial officer evaluate scheringplough disclosure control procedure end period cover k conclude scheringploughs disclosure control procedure effective conclude change scheringplough internal control financial reporting occur scheringplough recent fiscal quarter materially affect reasonably likely materially affect scheringploughs internal control financial reporting change business environment scheringplough operate scheringplough replace upgrade number information system process ongoing year connection change scheringploughs management internal control financial reporting disclosure control procedure management conclude new system effective respect control prior system management report internal control financial reporting management scheringplough corporation responsible establish maintain adequate internal control financial reporting scheringplough internal control system design provide reasonable assurance scheringplough management board director preparation fair presentation publish financial statement internal control system matter design inherent limitation system determine effective provide reasonable assurance respect financial statement preparation presentation scheringploughs management assess effectiveness scheringploughs internal control financial reporting december make assessment management criterion set forth committee sponsor organization treadway commission coso internal control integrate framework base assessment management believe december scheringploughs internal control financial report effective scheringplough independent register public accounting firm deloitte touche llp issue attestation report management assessment scheringplough internal control financial reporting firm report follow table content report independent register public accounting firm board director shareholder scheringplough corporation audit management assessment include accompany management report internal control financial reporting scheringplough corporation subsidiary company maintain effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion management assessment opinion effectiveness company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting evaluate management assessment testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion management assessment company maintain effective internal control financial reporting december fairly state material respect base criterion establish internal control integrate framework issue committee sponsor organization treadway commission opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission audit accordance standard public company accounting oversight board united states consolidated financial statement financial statement schedule year end december company report date february report include explanatory paragraph company adoption statement financial accounting standard sfas revise sharebased payment sfas employer account define benefit pension postretirement plan express unqualified opinion financial statement financial statement schedule deloitte touche llp parsippany new jersey february table content iii item director executive officer registrant information concern director nominee director incorporate reference proposal elect director oneyear term scheringplough proxy statement annual meeting shareholder information concern executive officer include file caption executive officer registrant information concern compliance section exchange act incorporate reference section beneficial ownership report compliance scheringplough proxy statement annual meeting shareholder information concern audit committee audit committee financial expert incorporate reference information audit committee board director practice committee board director scheringplough proxy statement annual meeting shareholder scheringplough adopt code business conduct ethic standard global business practice applicable employee include chief executive officer chief financial officer controller scheringploughs standard global business practice available investor relation section scheringplough website wwwscheringploughcom addition write copy material provide charge write office corporate secretary scheringplough corporation gallop hill road mail stop k kenilworth new jersey scheringplough intend satisfy disclosure requirement item form k amendment waiver provision standard global business practice post information website address specify item executive compensation information concern executive compensation incorporate reference executive compensation scheringplough proxy statement annual meeting shareholder information concern director compensation incorporate reference director compensation scheringploughs proxy statement annual meeting shareholder item security ownership certain beneficial owner management relate stockholder matter information concern security ownership certain beneficial owner management incorporate reference stock ownership scheringplough proxy statement annual meeting shareholder table content equity compensation plan information follow information relate plan equity security scheringplough issue employee director schere plough plan equity security issue nonemployee stock incentive plan certain stock option transferable family member employeeoptionee relate trust column column b column c number security remain available number security future issuance issue weightedaverage equity exercise exercise price compensation outstanding outstanding plan exclude option warrant option security reflect plan category right warrant right column equity compensation plan approve security holder stock incentive plan stock incentive plan stock incentive plan stock incentive plan director stock award plan na na equity compensation plan approve security holder scheringplough ireland approve profit sharing scheme na na total plan permit eligible employee work scheringplough irish subsidiary enjoy tax advantage christma bonus percent percent pay pass trustee trustee purchase share common stock open market allocate share employee account euro defer year employee employee sell withdraw share allocate account year item certain relationship relate transaction information concern certain relationship relate transaction incorporate reference certain transaction procedure relate party transaction director independence assessment scheringplough proxy statement annual meeting shareholder information concern director independence incorporate reference director independence scheringploughs proxy statement annual meeting shareholder item principal accountant fee service information concern principal accountant fee service incorporate reference proposal ratify designation deloitte touche llp audit scheringplough books account scheringplough proxy statement annual meeting shareholder iv item exhibit financial statement schedule follow document file report financial statement financial statement set forth item k financial statement schedule merckscheringplough cholesterol partnership combine financial statement index p age combine statement net sale contractual expense year end december combine balance sheet december combine statement cash flow year end december combine statement partner capital year end december note combine financial statement year end december independent auditor report schedule ii valuation qualifying account schedule list omit applicable require table content index exhibit indicate exhibit commission file number exhibit number description location amend restate certificate incorporation incorporate reference exhibit scheringplough q period end june b amend restate bylaw incorporate reference exhibit b scheringplough q period end june right agreement scheringplough bank new york date incorporate reference exhibit scheringplough file june june b form participation right agreement scheringplough chase incorporate reference exhibit scheringplough registration manhattan bank national association trustee statement form amendment file december file ci indenture date november scheringplough bank incorporate reference exhibit scheringplough k file new york trustee november cii supplemental indenture include form note date november incorporate reference exhibit scheringplough k file november ciii second supplemental indenture include form note date november incorporate reference exhibit scheringplough k file november civ global senior note incorporate reference exhibit civ scheringploughs k year end december cv global senior note incorporate reference exhibit cv scheringploughs k year end december director compensation plan amend restate effective june incorporate reference exhibit hiii scheringploughs q amendment september period end september bi stock incentive plan incorporate reference exhibit scheringplough q period end september bii amendment stock incentive plan effective february incorporate reference exhibit scheringplough q period end march biii amendment stock incentive plan effective february incorporate reference exhibit c scheringploughs k year end december c stock incentive plan amend february incorporate reference exhibit scheringplough k year end december stock incentive plan amend restate effective incorporate reference exhibit diii scheringploughs q amendment september period end september table content exhibit number description location ei letter agreement date november robert bertolini schering incorporate reference exhibit eiii scheringplough k plough year end december eii employment agreement effective change control date incorporate reference exhibit scheringplough k file december robert bertolini scheringplough corporation december eiii employment agreement date carrie cox incorporate reference exhibit scheringplough k file scheringplough eiv employment agreement date april fred hassan incorporate reference exhibit scheringplough k file april scheringplough ev employment agreement date december thomas p attach koestler phd scheringplough evi employment agreement date december raul kohan attach scheringplough evii letter agreement date march thomas j sabatino jr incorporate reference exhibit scheringplough q period scheringplough end march eviii employment agreement effective change control date april attach thomas j sabatino jr scheringplough eix form employment agreement effective change control attach scheringplough certain executive new agreement begin december f operation management team incentive plan amend restate effective incorporate reference exhibit mii scheringploughs q june period end september g cash longterm incentive plan amend restate effective january incorporate reference exhibit n scheringplough k year end december h longterm performance share unit incentive plan amend restate incorporate reference exhibit scheringplough k year effective january end december transformational performance contingent share program incorporate reference exhibit p scheringploughs k year end december j severance benefit plan amend restate effective december incorporate reference exhibit exi scheringplough q amendment april period end march k saving advantage plan amend restate effective june incorporate reference exhibit exiii scheringplough q period end september l supplemental executive retirement plan amend restate january attach table content exhibit number description location retirement benefit equalization plan amend restate january incorporate reference exhibit l scheringplough k year end december n executive incentive plan amend restate october incorporate reference exhibit ai scheringploughs k year end december defer compensation plan amend restate october incorporate reference exhibit scheringplough k year end december p amend restate define contribution trust incorporate reference exhibit aii scheringploughs k year end december q amend restate serp rabbi trust agreement incorporate reference exhibit g scheringploughs k year end december r cholesterol governance agreement date incorporate reference exhibit scheringplough k date scheringplough merck co inc party signatory thereto october amendment cholesterol governance agreement date incorporate reference exhibit scheringplough k file december scheringplough merck co inc october party signatory thereto master agreement date december schering incorporate reference exhibit scheringplough k file plough merck co inc party signatory thereto october u letter agreement date april relate consent decree incorporate reference exhibit scheringplough q period end march v distribution agreement scheringplough centocor inc date april incorporate reference exhibit u scheringplough amend k year end december file computation ratio earning fix charge attach standard global business practice cover employee include senior incorporate reference exhibit scheringplough k file financial officer september subsidiary registrant attach consent independent register public accounting firm attach independent auditor consent attach power attorney attach sarbanesoxley act section certification chairman board attach chief executive officer sarbanesoxley act section certification executive vice president attach chief financial officer table content exhibit number description location sarbanesoxley act section certification chairman board attach chief executive officer sarbanesoxley act section certification executive vice president attach chief financial officer compensatory plan contract arrangement certain portion exhibit omit pursuant request confidential treatment nonpublic information file separately security exchange commission pursuant rule b securities exchange act amend copy